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ABSTRACT OF THE DISSERTATION
Analysis of Minocycline as a Radioprotectant
by
Shalini Mehrotra
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, May 2012
Dr. Daila S. Gridley, Chairperson

Exposure to radiation is increasing in a variety of settings including space
exploration, diagnostic medical procedures and radiotherapy. Cells of the hematopoietic
system, such as white blood cells (WBC), are especially sensitive to radiation and their
decline can result in Acute Radiation Syndrome (ARS). Radiotherapy is often used for
cancers of the central nervous system (CNS), but includes the risk for normal tissue
damage, often leading to cognitive impairment. The literature suggests that tetracyclines
can be radioprotectors of the hematopoietic system with potential utility in radiation
emergencies and anticancer radiotherapy. Minocycline, a semisynthetic tetracycline
derivative, has anti-inflammatory, free radical scavenging, anti-apoptotic and antiangiogenic properties with exceptional penetration into the CNS. These qualities make it
a viable candidate for use in combination with radiotherapy for CNS tumors as a
normal tissue radioprotectant and for hematopoietoc recovery following whole-body
irradiation. This study was undertaken to determine the potential of minocycline as a
radioprotective agent of the hematopoietic system and CNS in response to whole-body
irradiation with 1, 2 and 3 Gy (γ-rays). C57BL/6 mice were injected with minocycline, 5
times beginning immediately before irradiation. Spleen, blood and brain were collected
on days 4 and 32 post-irradiation. WBC and other cell populations were determined in

xvii

the blood and spleen while cytokines were quantified in CD3-activated splenocytes and
homogenized brain supernatants. We also evaluated the impact of minocycline on DNA
synthesis and viability of human glioblastoma cells versus astrocytes and microglia.
Minocycline increased counts and percentages of splenic macrophages, granulocytes,
natural killer (NK), T and CD8+ T cells on day 4 and B cells on day 32. Minocycline upregulated interleukin-1α (IL-1α) which is radioprotective, as well as granulocytemacrophage colony stimulating factor (GM-CSF) and G-CSF that accelerate neutrophil
recovery at both time points post-exposure. Minocycline reversed the radiation-induced
IL-10 decrease in the brain on day 4 while increasing vascular endothelial growth factor
(VEGF), and lowering IL-1β on day 32. The drug did not protect glioblastoma cell lines
from radiation but increased the viability of astrocytes at lower doses. These data support
further testing of minocycline to counteract radiation insult to the hematopoietic system
and CNS.

xviii

CHAPTER ONE
INTRODUCTION

Radioprotectors
Radiotherapy is commonly used to treat a wide range of cancer types. Treatment
protocols aim to target cancer cells, while limiting damage to normal cells as much as
possible. Radiation, however, can also cause damage to normal cells, resulting in adverse
side effects depending on the sensitivity of the tissue and the dose of ionizing radiation
(Hosseinimehr 2007). If the damage is sublethal, the cells may not function normally
and could eventually progress to malignancy. Better tumor management using higher
radiation doses can be accomplished if the surrounding normal tissues are protected
against radiation insult. During space missions, normal cells and tissues of astronauts are
also exposed to radiation above levels currently deemed as safe for the general
population. A 2- to 3-year Mars mission could expose the astronauts to a total radiation
dose up to 3.0 gray (Gy)(Simonsen, Cucinotta et al. 1993). As human space exploration
proceeds and prevalence of radiation exposure due to the medical procedures (diagnostic
and therapeutic) increases, there is an urgent need to identify safe and effective normal
tissue radioprotectants.
A radioprotectant is a compound that is administered before exposure to ionizing
radiation to minimize radiation-induced toxicity to normal tissues. Thus, a
radioprotective compound should protect cells from ionizing radiation if present before or
during irradiation (Manori, Kushilevsky et al. 1986). Radioprotectants can serve as
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useful adjuncts during radiotherapy if they can enhance the tolerance of normal tissues
and not affect the radiosensitivity of tumors. Agents with these properties would
facilitate the use of higher radiation doses to improve treatment outcome. This could be
achieved if the radioprotector was well taken up by normal cells compared to tumor cells
or protect the oxygenated tissue more than the hypoxic tumor mass (Maisin 1998). The
biological use of many of the compounds currently under investigation is, however,
limited due to high cytotoxicity (Ritter 1981). An ideal radioprotector should protect
normal tissues without compromising the cytotoxic effect of radiation on tumor. In
essence the radioprotector should not interfere with the damaging effects of ionizing
radiation on tumors. This approach would increase therapeutic benefits of radiation
treatment.
Numerous approaches to radioprotection have been tried, including use of compounds
that act as free radical scavengers, facilitate DNA repair and induce production of growth
factors and cytokines (Maisin 1998). However, currently, the only Food and Drug
Administration (FDA)-approved radioprotectant for use during treatment of solid tumors
is amifostine (formerly WR-2721); but this compound is well known to have side effects
such as nausea, vomiting, and severe asthenia (Schuchter, Hensley et al. 2002). Clearly
there is a need to develop new radioprotectors and mitigators for normal tissue.

Acute Radiation Syndrome (ARS)
Exposure to ionizing radiation can cause a variety of physiological changes
known as ARS. ARS occurs following significant whole-body or partial-body radiation
exposure to doses >1 Gy administered at relatively high-dose rates (Waselenko,
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MacVittie et al. 2004). Different ranges of total-body irradiation manifest as different
forms of injury. The rapidly proliferating cells like the spermatocytes, hematopoietic
cells and cells of the gastrointestinal tract, are the most susceptible to radiation injury
(Waselenko, MacVittie et al. 2004). The main clinical types of ARS can be divided into
hematopoietic, gastrointestional and cerebovascular syndromes. As a rule, these
syndromes are manifested only when the entire body, or a substantial portion of it, is
exposed to photons, e.g., X-rays and γ-rays, or a combination of photons and particle
forms of radiation such as neutrons (Heslet, Bay et al. 2012). Each syndrome consists of a
prodromal phase, latent phase, manifest illness and finally recovery or death. The
prodromal phase generally lasts during the first 48 hours and can extend up to 6 days
post-exposure. This early phase can be characterized by anorexia, nausea, vomiting,
diarrhea, mild fever, conjunctivitis and skin erythema. During the latent phase, it appears
as though the person has recovered. However, this is transient and can last from several
days to a month. Manifest illness is comprised of severe depression of the immune
system and can last for several weeks. Recovery is generally a possibility if the person
survives this phase. Clinical management of ARS depends on the absorbed radiation dose
and its distribution into the body. It often includes administration of broad-spectrum
antibiotics (Kim, Pollard et al. 2009), as well as blood products and colony-stimulating
factors to regenerate granulocytes.

Hematopoietic Syndrome
One of the major factors in mortality following radiation is damage to the
hematopoietic system. The hematopoietic syndrome can occur even at lower doses
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compared to other syndromes because of the high radiosensitivity of the hematopoietic
cells (Dorr and Meineke 2011) which reside primarily in the bone marrow. After totalbody irradiation, injury to the hematopoietic system is clearly manifested in the form of
depletion in circulating blood cell populations (Samarth, Goyal et al. 2004).
Hematopoietic syndrome can occur after total- or partial-body exposure to radiation
doses above 1 Gy (Waselenko, MacVittie et al. 2004). It is associated with a dramatic
decrease in peripheral WBC, platelet count, red blood cell (RBC) count and, if
accompanied with the lack of prompt medical intervention that includes bone marrow
transplantation, can lead to death (Stone, Moulder et al. 2004).
A reduction in the populations of circulating blood cells can lead to septicemia,
hemorrhage, anemia, and death. Some novel radioprotective agents can stimulate,
maintain and/or induce proliferation of progenitor cells from bone marrow. Among them
are cytokines that can stimulate hematopoietic stem cells (Neta and Oppenheim 1988;
Moreb, Zucali et al. 1989; Neta, Oppenheim et al. 1991; Neta 1997). Figure 1.1 shows
the predicted time course of changes in various cell populations in response to 3 Gy
radiation, as depicted by the International Atomic Energy Agency (Vienna, Austria).
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Figure 1.1. Predicted time course of changes in various cell populations in response to 3
Gy radiation. International Atomic Energy Agency (http://www.iaea.org).
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Current Treatments for Radiation Injury to the Hematopoietic System
A quantitative relationship exists between the severity of infections and the
degree of neutropenia (Heslet, Bay et al. 2012). Management depends on the severity of
hematopoietic syndrome and involves administration of erythrocyte concentrate, blood
products and cytokines like G-CSF and GM-CSF. In more severe cases, bone marrow
transplant is a treatment option (Dainiak 2010). However, transplantation is not feasible
in emergencies involving a large number of people. Other radiation countermeasures are
required due to this reason. Currently, there are no FDA-approved countermeasures for
the management of ARS (Moroni, Coolbaugh et al. 2011).

Radiation and CNS Inflammation
Radiation is a major treatment option for tumors located close to or within the
CNS. Although the CNS is relatively radioresistant, recent studies have shown that the
neural precursor stem cells are particularly sensitive to radiation and even relatively low
doses of radiation can lead to impairment of adult postnatal neurogenesis. Neural
precursor stem cells undergo apoptosis at clinically relevant doses that do not otherwise
result in any overt tissue injury (Fike, Rola et al. 2007). Exposure of rats to high energy
iron particles resulted in an alteration in behavior even after exposure to doses as low as
0.1 Gy (Rabin, Joseph et al. 2000). Eradication of the cancer, however is accompanied by
damage to normal brain tissue and may impact cognition (Raber, Rola et al. 2004; Butler,
Rapp et al. 2006; Meyers and Brown 2006). Neurocognitive deficits are an especially
harmful side effect for children who undergo radiotherapy as a life-saving option.
Irradiation of brain tissue often results in inflammation (Moore, Olschowka et al. 2004;
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Moravan, Olschowka et al. 2011), i.e., migration of leukocytes such as neutrophils to the
site of damage. It is also believed that radiation induces a neuroinflammatory milieu of
pro-inflammatory cytokines and other factors, resulting in oxidative stress. This, in turn,
is responsible for the pathogenesis of radiation-induced brain injury (Rola, Fishman et al.
2008; Ramanan, Zhao et al. 2010). An acute response to radiation in the brain involves an
increase in inflammatory cytokines and mediators such as tumor necrosis factor-α (TNFα), IL-1β, inter-cellular adhesion molecule 1 (ICAM-1) and cyclooxgenase-2 (COX-2),
as well as activation of transcription factors such as nuclear factor kappa-light-chainenhancer of activated B cells (NF-kB) and activator protein 1 (AP-1) (Hong, Chiang et al.
1995; Raju, Gumin et al. 1999; Raju, Gumin et al. 2000). A chronic inflammatory
response in the brain following radiation injury can lead to inhibition of neurogenesis
(Monje, Mizumatsu et al. 2002). It has been estimated that 50% of adult and 100% of
pediatric cancer survivors who receive whole-brain irradiation for metastatic disease will
develop cognitive dysfunction (Ramanan, Zhao et al. 2010). This cognitive dysfunction is
associated with decline of postnatal hippocampal neurogenesis (Monje, Mizumatsu et al.
2002). Patients who are subjected to cranial radiotherapy for management of primary and
metastatic tumors form the most severe cases (~200,000/yr) (Abayomi 1996; Ramanan,
Zhao et al. 2010).

Current Treatments for Radiation Injury to CNS
There are no preventative approaches or long-term therapies for radiation-induced
cognitive impairment. Bevacizumab, a humanized monoclonal antibody against vascular
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endothelial growth factor (VEGF), has very recently shown promise as a treatment option
for radiation-induced necrosis in the brain (Matuschek, Bolke et al. 2011).

Minocycline and its Potential as a Radioprotectant
Minocycline is a broad-spectrum semi-synthetic second generation tetracycline
derivative. Tetracyclines are bacteriostatic compounds that exert their antimicrobial effect
by inhibiting protein synthesis. Minocycline has a broad range of activity against both
Gram-positive and Gram-negative bacteria. This drug is commonly used to treat
infections due to Neisseria meningitidis and multi-drug resistant Staphylococcus aureus.
It is readily absorbed in the gut when taken orally and patients have a low propensity for
developing antibiotic resistance. Therefore, it is prescribed for long-term use in the
management of acne and rosacea. On an average, a good safety record for long-term
usage has been established for minocycline (Seukeran, Eady et al. 1997).
Figure 1.2 shows the chemical structure of minocycline.
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C23H27N3O7

M.W.=457.5

Figure 1.2. Structure of Minocycline
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Potential for Protective Effects of Minocycline in the Periphery
Antibiotics have been employed as an important component in treating radiation
injuries to minimize risk for systemic infections and facilitate recovery of tissues such as
bone marrow and intestine (Thomas, Storb et al. 1976; Vriesendorp, Chu et al. 1994).
Recent studies have demonstrated that minocycline possesses other potentially
therapeutic effects that are distinct from its antimicrobial action. Of special importance is
an in vitro study of 13 drugs by Epperly et al.; they showed that minocycline protected
hematopoietic progenitor cells of the bone marrow from radiation damage (Epperly,
Franicola et al. 2010).
The above mentioned studies and other evidence support the testing of
minocycline as a radioprotectant. The drug may maintain the integrity and accelerate
the regeneration of hematopoietic progenitors in the bone marrow under conditions of
oxidative stress.

Potential for Protective Effects of Minocycline in the CNS
Yrjanheikki et al. were the first to report that minocycline protected hippocampal
neurons from death in a gerbil model of cerebral ischaemia (Yrjanheikki, Keinanen et al.
1998). Since then, minocycline has been reported to exert neuroprotective effects in
animal models of traumatic brain injury, cerebral ischemia, Parkinson’s disease,
amyotrophic lateral sclerosis, Huntington’s disease and multiple sclerosis (Kim and Suh
2009; Guimaraes, Freire et al. 2010). It is small (495 kDa), well tolerated and highly
lipophilic, properties which enable it to cross the blood-brain barrier (BBB) (Yong, Wells
et al. 2004). It penetrates through the cerebrospinal fluid (CSF) more rapidly than
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doxycycline and other tetracyclines (Macdonald, Kelly et al. 1973). Clinical trials with
minocycline are underway for various neurodegenerative diseases. Importantly, some
studies have demonstrated that minocycline protects retinal cells from light and oxidative
stress-induced damage (Leung, Lindlief et al. 2007) and can also play a role in inhibiting
angiogenesis (Maragoudakis, Peristeris et al. 1994). The retina of the eye is considered to
be part of the CNS, since it forms as an outgrowth of brain tissue during embryonic
development. Among the tetracycline derivatives, only minocycline possesses
neuroprotective properties (Good and Hussey 2003). Krauss et al. have reported that
minocycline, unlike tetracycline, possesses antioxidant and free radical scavenging
properties similar to vitamin E (Kraus, Pasieczny et al. 2005). Neuroprotection by
minocycline has also been attributed to its suppression of caspase activity (Stirling,
Khodarahmi et al. 2004). However, the neuroprotective mechanisms of minocycline
action have not yet been clearly defined. They can perhaps be attributed to the ability of
minocycline to reduce microglial activation and proliferation and suppression of proinflammatory cytokines like TNF-α and interferon-γ (IFN-γ). Microglial activation has
been implicated in inflammatory processes that lead to neuronal cell death in
neurodegenerative diseases (Dheen, Kaur et al. 2007). Indeed, microglial activation is the
hallmark of brain pathology. Kim et al. reported that tetracyclines and fluoroquinolones
can be robust protectors of the hematopoietic system and could be employed in scenarios
of radiation injury (Kim, Pollard et al. 2009). Minocycline has been shown to exhibit
neuroprotective actions by suppressing the activation and proliferation of microglial cells
(Filipovic and Zecevic 2008). Use of a neuronal cell radioprotectant such as minocycline
has potential to increase the possibility for cure without increasing risk for unwanted
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complications. Blocking neuronal inflammation has been shown to restore neurogenesis
(Monje, Toda et al. 2003). Owing to its anti-inflammatory and neuroprotective properties,
in combination with the other mentioned non-antimicrobial properties, the testing of
minocycline as a radioprotector/radiomitigator prompts further research.
The above mentioned studies support the testing of minocycline as a potential
drug for reducing radiation-induced CNS inflammation.

Minocycline and Tumor Suppression
It has been shown previously that tetracycline and its analogues can induce
apoptosis in a number of cancer cell lines in vitro e.g., melanoma, osteosarcoma, breast,
colorectal, and cervical carcinoma (Onoda, Ono et al. 2006). Sotomayor et al.
demonstrated that minocycline enhanced tumor growth delay when administered along
with therapies including melphalan, radiation, adriamycin and bleomycin (Sotomayor,
Teicher et al. 1992). These investigators also reported that addition of minocycline to
standard chemotherapy with cyclophosphamide actually resulted in delayed tumor
growth (Sotomayor, Teicher et al. 1992). Teicher et al. found that minocycline has
antitumor and cytotoxic properties which could be exploited in cancer treatment (Teicher,
Dupuis et al. 1995). Zucker et al. reported that minocycline was capable of inhibiting
melanoma cell activity in vitro (Zucker, Lysik et al. 1985). According to Du et al.,
minocycline inhibits the growth of tumor cells and attenuates ototoxicity when
administered along with the chemotherapeutic drug cisplatin (Du, Zhang et al. 2011).
Minocycline also exhibited antitumor effect on glioma cells and ovarian cancer cell lines
{Markovic et al. 2011, Pourgholami et al. 2012).
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The above mentioned studies and evidence support the testing of minocycline
along with radiation therapy as a combined treatment option for enhancing the
cytotoxic effect of radiation on tumors.

Purpose of this Study
The increasing role of radiation therapy in cancer management along with the
threat of nuclear or radiological terrorism urges the need for discovering agents for
prophylaxis, mitigation, and treatment of radiation injury. The sensitivity of the
hematopoietic system to ionizing radiation and the lack of agents to prevent or mitigate
the damage gives utmost significance to our study. The purpose of the proposed study is
to characterize a novel radioprotector with special emphasis on its impact on the
hematopoietic system and CNS. The objectives are to characterize and identify
minocycline-induced immunological effects in a mammalian model irradiated with
space- and clinically-relevant doses and to determine if the drug affects glioblastoma and
non-tumor cell response to radiation when exposed in culture.The conditions are unique
and will provide new information relevant to a broad range of clinical applications.
In order to test the potential of minocycline in radioprotection, the following
hypotheses were proposed: 1) Minocycline will protect the hematopoietic system and
CNS against the damaging effects of whole-body irradiation; 2) The radioprotective
effect of minocycline will be associated with increased capacity to produce antiinflammatory factors; and 3) Minocycline will radioprotect normal CNS cells, but
not glioblastoma cells, and may even exhibit tumoricidal properties. These
hypotheses were addressed in the following specific aims.
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Specific Aim 1: Determine if minocycline protects immune system cells against
radiation in a mouse model.
A. Evaluate survival and distribution of leukocyte populations/subpopulations in
blood and spleen.
B. Characterize the cytokine profile of splenocytes to determine the capacity of
minocycline to facilitate hematopoiesis post-irradiation.

Specific Aim 2: Determine if minocycline protects the brain in an irradiated mouse
model by reducing inflammation.
A. Perform analysis of cytokines/chemokines in the brain to determine if
minocycline has potential to reduce inflammation.
B. Assess gene expression by quantitative reverse-transcription polymerase chain
reaction (qRT-PCR), characterizing genes related to common cytokines and
neurotoxicity.

Specific Aim 3: Determine if minocycline has a differential radioprotective effect on
survival (DNA synthesis and viability) of glioblastoma versus non-malignant cells.
A. Determine if minocycline protects brain tumor cell lines (human U87MG, T98G,
A172) from cytotoxic effects of ionizing radiation.
B. Determine if minocycline protects non-tumorigenic cell lines present in the CNS
(human astrocytes and microglia) from the cytotoxic effects of ionizing radiation.
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Abstract
Background/Aim: To evaluate the impact of an antibiotic, minocycline on several
immune parameters in response to radiation in a mouse model. Materials and Methods:
C57BL/6 mice were treated with minocycline (i.p.) for 5 days beginning immediately
before radiation with 1- 3 Gy 60Co γ-rays. Spleen and blood were collected on day 4 postirradiation. Cell populations were determined in the blood and spleen. Splenocytes were
activated with anti-CD3 antibody for 48 h and cytokines were quantified. Results:
Minocycline increased the counts and/or percentages of splenic macrophages,
granulocytes, NK, T and CD8+ T cells (P<0.05 vs. radiation alone). Minocycline
significantly increased IL-1α and β which are radioprotective, as well as GM-CSF and
G-CSF that accelerate neutrophil recovery (P<0.05 vs. radiation alone), while
suppressing cytokines that could prevent hematopoiesis, e.g. MIP-1α, TNF-α and IFN-γ.
Conclusion: These data indicate that minocycline should be further tested for restoration
of the hematopoietic system after radiation exposure.
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Introduction
Radiation exposure is a highly significant concern in events of nuclear disasters.
Although cytokines and growth factors have been extensively researched as potential
radioprotectors and radiomitigators (Dainiak, Waselenko et al. 2003) very few effective
countermeasures are available. Consequently, protection against radiation damage to
normal tissues is very important to the Departments of Defense (DOD), Energy (DOE)
and Homeland Security, as well as the National Aeronautics and Space Administration
(NASA). Radiation in the space environment is above levels deemed to be safe on Earth
and crew members could be exposed to doses as high as 1-3 Gray (Gy) during solar
particle events (SPE) (Simonsen, Cucinotta et al. 1993). In addition, radiation therapy is
widely employed as a treatment option for a wide range of malignancies. Bone marrow
transplant recipients also receive doses of radiation that can result in hematopoietic
syndrome. Despite advancements in treatment strategies, toxicity to normal tissue still
remains a cause for concern.
Exposure to ionizing radiation can cause a variety of physiological changes
collectively known as Acute Radiation Syndrome (ARS). One of the major factors in
mortality in patients with ARS is damage to the hematopoietic system. Exposure to doses
~0.5-1 Gray (Gy) or above (gamma or X-rays) can compromise the hematopoietic system
to some extent (Singh, Singh et al. 2011). Whole-body irradiation between doses ranging
from approximately 1 to 8 Gy can lead to “hematopoietic syndrome” characterized by
dramatic decrease in peripheral white blood cell (WBC), platelet and, red blood cell
(RBC) counts and, if accompanied with the lack of prompt medical intervention that
includes bone marrow transplantation, can rapidly lead to death (Singh, Singh et al.
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2011). Hematopoietic progenitor stem cells have a restricted capacity of cell division
after total-body irradiation above 2 to 3 Gy (Waselenko, MacVittie et al. 2004).
Numerous complications are possible, including infections and internal hemorrhage.
Medical management of ARS often includes administration of broad-spectrum antibiotics
(Kim, Pollard et al. 2009), as well as blood products and colony-stimulating factors to
regenerate granulocytes. Although there are currently no drugs approved by the Food and
Drug Administration (FDA) for treatment of ARS, the use of growth factors like
granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colonystimulating factor (GM-CSF) is included as part of the standard therapy for ARS in the
United States, resulting in improved function and numbers of macrophages and
granulocytes (Heslet, Bay et al. 2012). Daily injections may be needed and side effects
can occur. In more severe cases, bone marrow transplant is a treatment option. However,
since this is not feasible in emergencies involving a large number of people, other
radiation countermeasures are required.
Antibiotics have been employed as an important component in treating radiation
injuries to minimize risk for systemic infections and facilitate recovery of tissues such as
bone marrow and gastrointestinal tract (Vriesendorp, Chu et al. 1994). Minocycline, a
semisynthetic, second generation tetracycline derivative, is often used to treat infections
due to Neisseria meningitidis and multi-drug resistant Staphylococcus aureus. Recent
studies have demonstrated that minocycline possesses other potentially therapeutic effects
that are distinct from its antimicrobial action. It is reported to be neuroprotective and
antiapoptotic (Stirling, Koochesfahani et al. 2005). Tikka et al. demonstrated
radioprotection of neuronal cells through minocycline by the reduction in levels of lactate
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dehydrogenase, DNA fragmentation and microglial cell numbers (Tikka, Usenius et al.
2001). Krauss et al. found that minocycline, unlike tetracycline, possesses antioxidant
and free radical scavenging properties similar to vitamin E (Kraus, Pasieczny et al. 2005).
Tetracyclines have been reported to have radioprotective properties for hematopoietic
cells by Kim et al. (Kim, Pollard et al. 2009). In this context, we hypothesized that
minocycline has potential to facilitate regeneration of immune cell populations following
whole-body irradiation. We further hypothesized that minocycline would enhance
capacity to secrete cytokines that facilitate hematopoiesis, thus minimizing potential for
serious complications associated with ARS. Day 4 was selected for the analyses because
ARS can result in death within a few days. Thus, an agent that protects close to the time
of irradiation and/or rapidly enhances hematopoiesis would be of considerable value. In
addition, immune depression at the day 4 time point is close to the nadir after 1-3 Gy
whole-body irradiation in the C57BL/6 mouse model used in the present study.

Materials and Methods
Animals and Experimental Design
Female C57BL/6 mice (n = 80; 8-9 weeks of age; Charles River Breeding
Laboratories, Inc. Hollister, CA, USA) were housed in large plastic cages (n=10/cage)
and acclimatized for 5-7 days under standard vivarium conditions. Animals were divided
into 8 groups (10 mice/group): (a) deionized water (dH20) + 0 Gy (b) dH2O + 1Gy; (c)
dH2O + 2 Gy; (d) dH2O + 3 Gy; (e) Minocycline + 0 Gy; (f) Minocycline + 1 Gy; (g)
Minocycline + 2 Gy; and (h) Minocycline + 3 Gy. To characterize the early effects of the
drug, animals were rapidly euthanized on day 4 post-irradiation using 100% CO2 in
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compliance with the recommendations of the National Institutes of Health and the Panel
of Euthanasia of the American Veterinary Medical Association. The protocol used was
approved by the Loma Linda University Institutional Animal Care and Use Committee.

Drug Treatment and Irradiation
Minocycline was purchased from Triax Pharmaceuticals, LLC, Cranford, NJ,
USA. Animals in the respective groups were given an intraperitoneal (I.P) injection of
minocycline hydrochloride (45mg/kg in a volume of 0.1 ml) immediately before
irradiation or I.P. injections of dH2O. The dose of drug and timing of the injections was
based on previous reports (Yrjanheikki, Keinanen et al. 1998; Yrjanheikki, Tikka et al.
1999; Zhang, Lei et al. 2004). An Eldorado unit containing a Co-60 source was used to
administer whole-body radiation at a dose rate of 1.58 Gy/min for a total dose of 1, 2 or 3
Gy to the mice in the respective groups. Non-anesthetized mice were placed individually
into rectangular plastic aerated boxes (30 x 30 x 85 mm3). A second injection of
minocycline (45mg/kg) or dH2O was administered to the appropriate groups immediately
after irradiation. This was followed by 3 consecutive injections of minocycline (22.5
mg/kg) or dH2O on the following three days post-irradiation. Similar treatment was given
to sham-irradiated groups, but without the radiation.

Blood and Spleen Collection
Blood was obtained by cardiac puncture immediately after euthanasia in 1 ml
tuberculin syringes containing [K2]EDTA. Spleens were harvested and single-celled
suspensions were prepared by processing the spleens in complete RPMI 1640 medium
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(Irvine Scientific, Santa Ana, CA, USA) using sterile applicator sticks. Spleens were
washed and centrifuged to remove debris followed by lysis of RBC using 2 ml lysis
buffer for 4 min at 4˚C. Splenic leukocytes were suspended in 2 ml of RPMI 1640
medium for further analysis.

Relative Spleen Mass (RSM)
Body weight was recorded for each mouse at the time of euthanasia and the
spleens were weighed immediately after excision. Relative spleen mass was calculated as
follows: RSM = spleen mass (mg)/body mass (g).

Analysis of Cell Populations in Spleen and Blood
Spleen and blood cells were analyzed on an automated analyzer (HESKATM Vet
ABC- Diff Hematology Analyzer, HESKA Corp., Waukesha, WI, USA). WBC counts, as
well as numbers and percentages of lymphocytes, granulocytes, and
monocytes/macrophages were obtained. For the blood, additional values were obtained as
follows: platelet (PLT) count, mean platelet volume (MPV), hematocrit (HCT), mean
corpuscular hemoglobin (MCH), mean corpuscular HGB concentration (MCHC), mean
corpuscular volume (MCV), RBC distribution width (RDW), red blood cell (RBC) count
and hemoglobin (HGB).

Flow Cytometry Analysis of Lymphocyte Populations in Spleen
The percentage of specific lymphocyte populations in the spleen was determined
using monoclonal antibody (mAb) mixtures purchased from Pharmingen, San Diego, CA,
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USA. A direct staining method was used to evaluate a minimum of 5,000 gated events for
each sample with a FACSCaliburTM flow cytometer and CellQuestTM software version
3.1 (Becton Dickinson, Inc., San Jose, CA, USA). The mAb were conjugated with
fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), allophycocyanin (APC), or
peridinin chlorophyll protein (PerCP). First, the CD45 marker was used to identify the
leukocytes; lymphocytes were then gated on CD45 and side scatter. mAb specific for
CD3 (T cells), CD4 (T helper or Th subset), CD8 (T cytotoxic or Tc subset), CD19 (B
cells), and NK1.1 (NK cells) were used for further analysis. T regulatory (Treg) cell
analysis was carried out with a staining kit which included FJK-16s*PE (anti-Foxp3),
CD4*FITC, and CD25*APC (eBioscience, Inc., San Diego, CA, USA). The CD4 CD25
+

+

T cells, both with and without Foxp3, were quantified by gating on side scatter and the
CD4 cells, followed by analysis of the CD25 versus FJK-16s (Foxp3 ) subset.
+

+

+

+

Activation of Splenocytes Using Anti-CD3 Coated Plates
The splenocytes were quantified after lysis of RBC using an automated
hematology analyzer (HESKA Corp.). The concentration of splenocytes was adjusted to
2x106 cells/ml with complete RPMI 1640 medium and 100 μl/well was dispensed into
96-well plates coated with immobilized anti-CD3 antibody (anti-Mouse CD3 BioCoatTM
T-Cell Activation, 96-well Assay Plates, BD Pharmingen, San Diego, CA, USA). Onehundred μl of RPMI 1640 was added to each well to make the total volume equal to 200
μl/well. This procedure results in the activation of the T cell receptor (TCR)/CD3
signaling machinery. The plates were incubated at 37˚C for 48 h and supernatants were
harvested after 48 h and stored in -80˚C until further analysis.
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Cytokine Analysis.
Spleen supernatants from -80˚C were thawed and analyzed for 22 different
cytokines and chemokines using the Mouse Cytokine/Chemokine Milliplex MAP Kit
(Millipore, Billerica, MA, USA). The cytokines/chemokines evaluated were as follows:
interleukin-1α (IL-1α), IL-1β, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p70), IL-13, IL15, IL-17, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage
(GM)-CSF, interferon-γ (IFN−γ), IFN-γ-induced protein 10 (IP-10), keratinocyte
chemoattractant (KC, also known as CXCL1), monocyte chemotactic protein-1 (MCP-1),
macrophage inflammatory protein-1α (MIP-1α), regulated upon activation, normal T-cell
expressed and secreted (RANTES) and tumor necrosis factor-α (TNF-α). Vascular
endothelial growth factor (VEGF) was analyzed in the anti-CD3-activated supernatants
using a VEGF enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems,
Minneapolis, MN, USA).

Statistical Analysis
The data were analyzed using one-way or two-way analysis of variance
(ANOVA). Tukey’s test was performed for pair-wise multiple comparisons when
indicated. Means and standard errors of means (SEM) are presented here; results from
each mouse were included in the analyses. A P value of <0.05 indicated significance.
SigmaStatTM software, version 2.03 (SPSS Inc., Chicago, IL, USA) was used to analyze
the data.
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Results
Relative Spleen Mass
As indicated in Figure 2.1, radiation generally decreased the spleen mass relative
to body mass, i.e., the RSM (P<0.05). Although there was no minocycline x radiation
interaction, treatment with the drug increased RSM regardless of radiation. In post-hoc
analysis, minocycline significantly (P<0.05) increased RSM in all radiation groups
except 3 Gy, where a trend for higher RSM was present (P<0.1).
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Figure 2.1 Relative Spleen Mass. Each bar represents the mean ± SEM for n=10
mice/group. Two-way ANOVA: §, P<0.05 for main effect of radiation; †, P<0.05
for main effect of drug. Tukey test: *, P<0.05 dH2O vs. Minocycline within each
radiation dose; a, P<0.05 vs 0 Gy within dH2O groups; b, P<0.05 vs 0 Gy within
Minocycline groups.
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WBC and Leukocyte Populations in Blood
Figure 2.2 shows the counts and percentages of lymphocytes, monocytes and
granulocytes in the blood. Radiation generally reduced the counts of all three of these cell
types (P<0.05), resulting in a significant radiation dose-dependent decrease in total WBC
number. Addition of the drug did not significantly enhance any of the cell counts. The
drug-induced decrease in lymphocytes was also apparent in the total WBC counts at 0 Gy
(P<0.05 vs. dH2O) (Figure. 2). In terms of percentages, the granulocytes increased in the
presence of the drug at all radiation doses while the lymphocyte percentages decreased
(P<0.05). The changes in eosinophils counts and percentages were similar to the overall
pattern of changes noted for granulocytes (Table 2.1).
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Figure 2.2 Leukocyte Populations in Blood. The data were obtained using an automated
hematology analyzer. Each bar represents the mean ± SEM for n=9-10 mice/group. Twoway ANOVA: §, P<0.05 for main effect of radiation; †, P<0.05 for main effect of drug; ‡,
P<0.05 for interaction between radiation and minocycline, Tukey test: *, P<0.05 dH2O vs
Minocycline within each radiation dose; a, P<0.05 vs 0 Gy within dH2O groups; b,
P<0.05 vs 0 Gy within Minocycline groups.
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Table 2.1. Counts and Percentages of Eosinophils in Blood and Spleen. The data were
obtained using an automated hematology analyzer (n=8-10 mice/group). Tukey test
(within dH2O or Minocycline): *, P<0.05 dH2O vs. Minocycline within each radiation
dose; a, P<0.05 vs 0 Gy within dH2O groups; b, P<0.05 vs 0 Gy within Minocycline
groups.
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0 Gy
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2 Gy
1.02*
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3 Gy
b

0.6
± 0.04
b
4.6*
± 0.1

WBC and Leukocyte Populations in Spleen
The distribution of lymphocytes, macrophages and granulocytes in the spleen is
shown in Figure 2.3. Radiation generally caused a decline in the counts of these three
leukocyte types (P<0.05). Treatment with minocycline caused a significant increase in
granulocyte and macrophage counts both in the 0 Gy and 2 Gy irradiated groups
(P<0.05), resulting in a significant main effect of drug. The pattern of changes in these
leukocyte types was reflected in the total WBC counts (Figure. 2.3). A significant
increase in granulocyte percentages was observed in the presence of minocycline in the 0
Gy, regardless of radiation (P<0.05). The lymphocyte percentages decreased significantly
in all groups (P<0.05). Splenic eosinophil counts and percentages showed similar
patterns as the granulocytes (Table 2.1).
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Figure 2.3. Leukocyte Populations in Spleen. The data were obtained using an automated
hematology analyzer. Each bar represents the mean ± SEM for n=9-10 mice/group. Twoway ANOVA: §, P<0.05 for main effect of radiation; †, P<0.05 for main effect of drug,
Tukey test: *, P<0.05 dH2O vs Minocycline within each radiation dose.
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Flow Cytometric Analysis of Lymphocyte Populations in Spleen
Radiation caused a decrease in the T, B and NK cell counts (P<0.05, Figure. 2.4).
There were main effects of minocycline on the T cell and NK cell populations (P<0.05).
In the post-hoc analysis, addition of the drug significantly increased the T cell counts at 0
Gy, 2 Gy and 3 Gy (P<0.05 vs. the counterpart groups without drug). Minocycline alone
increased the B cell counts in the 0 Gy group (P<0.05). Although drug-treated groups
showed consistently higher NK cell counts, significance was found only at 2 Gy
(P<0.05).
Consistent with the total T cell count, radiation caused a decline in the CD4+ Th and
CD8+ Tc cells (P<0.05, Figure. 2.4). While there was no significant minocycline impact
on these two subsets, the high counts in the 0 Gy and 2 Gy groups (P<0.05) resulted in a
main effect of the drug (P<0.05). Both radiation and minocycline generally increased
CD4:CD8 ratios (P<0.05). However, for radiation this was primarily due to changes in
the 2 and 3 Gy groups. Treatment with the drug generally mitigated or abolished the
radiation-induced increases at the higher doses (P<0.05), resulting in a significant drug x
radiation interaction (P<0.05).
When looking at the percentages (Figure. 2.5), radiation caused a decrease in B cells
with corresponding increases in the T and NK cell populations (P<0.05). Since
minocycline caused a significant proportional increase in B cells at 0 Gy (P<0.05), there
was a significant main effect of the drug (P<0.05) and a drug x radiation interaction
(P<0.05). Radiation-induced increases in NK cell percentages were generally augmented
when mice were treated with minocycline. However, in post-hoc analysis, the drug-
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induced increase reached significance only in the 2 Gy group (P<0.05), resulting in a
drug x radiation interaction (P<0.05).
Overall, radiation increased Th cell percentages while decreasing Tc cells (P<0.05,
Figure. 2.5). The drug did not significantly impact the proportion of Th cells. Although,
the drug caused an increase in Tc cell percentages (P<0.05), significance was found only
at 2 Gy in post-hoc analysis (P<0.05); this led to a significant drug x radiation interaction
(P<0.05).
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Flow Cytometric Analysis of CD4+CD25+Foxp3+ T Cells in Spleen
Radiation generally increased the CD4+CD25+ T cell counts (Figure. 2.6). Addition
of minocycline caused a significant increase at 0 Gy and 2 Gy (P<0.05). This resulted in
significant main effects of radiation and drug on these cells (P<0.05). Radiation also
caused a significant decrease in the CD4+CD25+Foxp3+ Treg cell counts (P<0.05).
Although minocycline-treated groups had consistently higher counts, significance was
found only at 0 Gy (P<0.05). This resulted in significant main effects of radiation and
drug on the CD4+CD25+Foxp3+Treg population (P<0.05).
While radiation generally increased the percentages of CD4+CD25+ T cells with
increasing dose, addition of minocycline significantly enhanced the effect of radiation at
1 Gy and 2 Gy (P<0.05; Figure. 2.6). This resulted in main effects of radiation and drug
on CD4+CD25+ T cell percentages (P<0.05). Radiation at 2 Gy and 3 Gy increased the
CD4+CD25+Foxp3+Treg cell percentages significantly (P<0.05). At 1 Gy, the percentage
of these cells was higher compared to the group with no drug (P<0.05).
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Cytokines in Spleen Supernatants
Numerous changes occurred in cytokine levels that were dependent on
minocycline, radiation, or both. Hence, for the sake of clarity in the discussion, as well as
simplicity, each cytokine was assigned to one of two groups. Group I included cytokines
that went up in the presence of the drug, while Group II included cytokines that went
down in the presence of the drug.

Group I Cytokines
This group included G-CSF, GM-CSF, IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-10, IL13, IL-17 and RANTES (Figure.2.7). Two-way ANOVA showed that radiation had a
significant main effect (P<0.05) on the levels of all of these cytokines except IL-10, IL17 and RANTES, while a main drug effect was noted for all except IL-5. A drug x
radiation interaction (P<0.05) was noted for all of the cytokines in this group except for
IL-10 and RANTES.
Post-hoc Tukey analysis revealed that minocycline significantly enhanced the
concentrations of IL-13 and RANTES in non-irradiated and all irradiated groups
compared to their counterparts that did not receive the drug (P<0.05). Significant druginduced increases in G-CSF, GM-CSF and IL-1β occurred in all irradiated groups. With
respect to the remaining cytokines, spleen supernatants from irradiated mice treated with
minocycline had significantly higher levels of IL-1α, IL-4, IL-5, IL-6, IL-10 and IL-17
compared to their counterparts exposed to 1, 2 and/or 3 Gy (P<0.05).
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Group II Cytokines
This group consisted of IFN-γ, TNF-α, MCP-1, MIP-1α, KC, IP-10, IL-7, IL12(p70), IL-2, VEGF and IL-15 (Figure 2.8). Two-way ANOVA showed that radiation
had a significant main effect on the levels of all of these cytokines except IL-12(p70) and
that minocycline had a main effect on all of them (P<0.05). A significant drug x radiation
interaction was noted for IFN-γ, TNF-α, MCP-1, KC, IL-7, IL-12(p70) and IL-2
(P<0.05).
The post-hoc Tukey test revealed that radiation, especially at the higher doses,
significantly enhanced the levels of IFN-γ, TNF-α, MCP-1, MIP-1α, KC, IP-10 and
VEGF and decreased the levels of IL-2 and IL-7 compared to 0 Gy (P<0.05). However,
addition of minocycline frequently minimized these radiation-induced changes. Mice
treated with the drug had significantly lower IFN-γ, MIP-1α, IL-7 and VEGF
concentrations in spleen supernatants (P<0.05) compared to their irradiated counterparts,
regardless of dose; low levels were also noted compared to 0 Gy (P<0.05). In addition,
the drug reduced the enhancing effects of radiation on MCP-1, KC, IP-10 and IL-15,
although statistical significance was not obtained at all radiation doses.
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Discussion
Our study is unique in that it characterized the impact of minocycline on
important immune parameters relevant to ARS in an irradiated mammalian model. In
essence, the results indicate that the drug has potential to promote hematopoietic recovery
after radiation exposure. The significantly increased spleen mass relative to body mass,
i.e. the RSM, is a broad indicator that supports minocycline as an enhancer of
hematopoiesis. Indeed, spleen weight has long been used as an index for determining
hematopoietic recovery after irradiation (Popp, Congdon et al. 1965).
A serious consequence of radiation injury is bone marrow failure, resulting in
leukopenia that can influence morbidity and mortality (Gale 1987). Agents that act as
radiation protectants/mitigators when used near the time of radiation exposure are
urgently needed. Many of the compounds under investigation stimulate the differentiation
of stem cells in bone marrow (Citrin, Cotrim et al. 2010). In the present study, there were
numerous differences among groups in cytokine concentrations and cell distribution
patterns. Since the major goal was to quantify the efficacy of minocycline as a
radioprotectant, as well as for the sake clarity, most of the remainder of the discussion is
divided into two sections based on the modulatory effects of the drug. Group I cytokines
were generally increased by minocycline, whereas the Group II cytokines were
decreased.

Group I: Cytokines Up-Regulated by Minocycline and Related Cell
Populations
Treatment with minocycline increased G-CSF, GM-CSF and IL-1β in spleen
supernatants from irradiated mice. Furthermore, these increases were incrementally
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enhanced with increasing radiation dose. Similar, although less pronounced, radiationdependent drug effects were noted in IL-1α, IL-4, IL-5 and IL-6.
Although T cells in the spleen samples were activated with anti-CD3 mAb, other
cell types (e.g., fibroblasts), may have contributed to the levels of G-CSF, GM-CSF, IL-5
and IL-6, particularly in the groups treated with minocycline (Baiocchi, Scambia et al.
1993). However, the pattern for all of these cytokines is remarkably similar to the
granulocyte percentages in the spleen (as well as in blood). This is important because the
assay involved a constant number of leukocytes per well and proportional differences
likely played a dominant role in the cytokine response. Neutrophils tend to persist when
microenvironmental signals that involve infection are present (Colotta, Re et al. 1992)
and proportional increase in this population may be due to similar signals generated by
radiation-induced cell debris. This increased survival could lead to increases in the
presence of cytokines produced by this population.
Indeed, neutrophils, the major type of granulocyte, and monocytes can secrete
GM-CSF, IL-1α and IL-1β (Cassatella 1995). In addition, GM-CSF induces production
of IL-1, IL-6 and G-CSF by neutrophils (Cicco, Lindemann et al. 1990). Although IL-1α
and IL-1β are two distinct cytokines, they bind to the same receptors (Luheshi, Rothwell
et al. 2009). Regardless of the source, a minocycline-induced increase in these cytokines
is important because they can be radioprotective or aid in recovery post-exposure (Neta
1997). For instance, lethality due to total-body irradiation is decreased substantially by GCSF treatment (Sureda, Valls et al. 1993). G-CSF and GM-CSF hasten myeloid
progenitor cell proliferation (Okano, Suzuki et al. 1989); GM-CSF also inhibits radiationinduced apoptosis (Collins, Marvel et al. 1992) and promotes eosinophil growth and
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function(Owen, Rothenberg et al. 1987). Administration of IL-1 has improved survival in
animals (Peterson, Adamovicz et al. 1994). Radioprotective mechanisms of IL-1 include:
a) induction of bone marrow cells into the relatively radioresistant S phase of the cell
cycle (Neta, Sztein et al. 1987); b) induction of manganese superoxide dismutase
(MnSOD) (Eastgate, Moreb et al. 1993) which protects against oxidative stress (Borrelli,
Schiattarella et al. 2009); and c) facilitation of granulopoiesis (Gershanovich, Filatova et
al. 2001). Interestingly, some researchers also mention that IL-1 can be cytotoxic to
tumors (Neta, Douches et al. 1986).
Although the drug generally increased IL-4, IL-5 and IL-6, its impact was most
prominent in the mice that also received 3 Gy. While a common factor among these
cytokines is activation of T or B cells (Hirano, Yasukawa et al. 1986), they also have
other activities. IL-4 and IL-5 are Th2 cell-derived cytokines (Kopf, Le Gros et al. 1993),
IL-4 stimulates hematopoietic progenitor cell proliferation (Peschel, Paul et al. 1987) and
IL-5 promotes proliferation and differentiation of eosinophils (Lampinen, Carlson et al.
2004). The up-regulation of IL-5 in the presence of minocycline may explain the
correlative increase in eosinophils. Similar patterns were observed for IL-6, a cytokine
produced by dendritic cells, macrophages and B cells (Diehl and Rincon 2002) that
promotes differentiation of the Th2 lineage while inhibiting Th1 cell differentiation
(Diehl and Rincon 2002). IL-6 enhances hematopoietic recovery by accelerating
mutilineage hematopoiesis and increasing myeloid progenitors (Okano, Suzuki et al.
1989; Neta 1997); its administration after lethal radiation promotes survival in animals
(Peterson, Adamovicz et al. 1994).
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For IL-10 and IL-17, the drug response was biphasic, where significant druginduced increases occurred only in the 1 Gy and 3 Gy treated mice. Values for the 0 Gy
and 2 Gy groups, however, were consistently higher when minocycline was included. IL10 is produced by macrophages, Th2 cells and especially Treg cells (Asadullah, Sterry et
al. 2003), while IL-17 is produced by the CD4+ (Fossiez, Djossou et al. 1996) and CD8+
T cell subsets (Hinrichs, Kaiser et al. 2009). However, the pattern of secretion was not
reflected in the proportions of the mentioned cells. IL-10 inhibits the suppressive activity
of IFN on hematopoiesis (Geissler, Kabrna et al. 2002). The minocycline-induced
increase in IL-10 is in accordance with previous observations (Lee, Yune et al. 2003). An
interesting additional point is that IL-10 may decrease risk for fibrosis (Nelson, Tu et al.
2003; Zhang, Zheng et al. 2007), a serious late consequence of radiation treatment. IL-17,
similarly to IL-10, induces the production of hematopoietic cytokines, e.g. IL-6 and GCSF (Fossiez, Djossou et al. 1996).
IL-13 and RANTES, were increased by minocycline, but radiation had no
detectable influence. In contrast to other cytokines in Group I, IL-13 is produced by Th2
(McKenzie, Emson et al. 1998), NK (Hoshino, Winkler-Pickett et al. 1999) and dendritic
cells (Bellinghausen, Brand et al. 2003), as well as eosinophils (Gessner, Mohrs et al.
2005; Spencer, Szela et al. 2009). The minocycline-induced increases found here are
consistent with reports that the drug preferentially stimulates Th2 cells over Th1 (Chen,
Ma et al. 2011), thus enhancing IL-13 production. Furthermore, the high eosinophil
percentages observed in the presence of the drug could also contribute to this response.
Since IL-13 stimulates the growth of hematopoietic progenitor cells (Jacobsen,
Okkenhaug et al. 1994), minocycline could help speed up recovery. RANTES is secreted
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by CD8+ T cells (Walzer, Marcais et al. 2003; Catalfamo, Karpova et al. 2004), including
memory T cells that tend to be relatively radioresistant (Yao, Jones et al. 2011). This
could explain the lack of a radiation response on the level of this chemokine despite an
overall decrease in total lymphocyte proportions. NK cells also produce RANTES (Zeng,
Chen et al. 2006) and this correlated with increased NK cell percentages. RANTES
attracts monocytes, eosinophils and T cells to sites of tissue damage (Alam, Stafford et al.
1993; Gao, Kuhns et al. 1993), is required for normal T cell function (Makino, Cook et
al. 2002), and increases CD8+ T cell counts (Crawford, Angelosanto et al. 2011).

Group II: Cytokines/Chemokines Down-Regulated by the Drug and
Related Cell Populations
While radiation increased production capacity for IFN-γ, TNF-α, MCP-1, MIP1α, KC, and IP-10, minocycline dramatically reduced their expression. Since many of
these cytokines inhibit hematopoietic activity, the minocycline-induced decreases further
support a role for this drug in hematopoietic recovery. The low level of IFN-γ and TNF-α
noted here is consistent with the literature (Kloppenburg, Verweij et al. 1995). Both of
these cytokines can inhibit hematopoiesis, but also have potent pro-inflammatory effects
(Peetre, Gullberg et al. 1986; Murase, Hotta et al. 1987; Eng, Car et al. 1995). Activation
of the p38 mitogen-activated protein kinase (p38 MAPK) pathway can lead to
suppression of hematopoiesis. This pathway also activates TNF-α and IFN-γ which are
myelosuppressive cytokines (Navas, Mohindru et al. 2006). Minocycline has been shown
to inhibit the p38 MAPK pathway (Tikka, Fiebich et al. 2001). The drug may be helpful
in restoration of hematopoiesis because it inhibits this pathway.
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MCP-1 is produced by keratinocytes and attracts monocytes, basophils and T cells
(Nakamura, Williams et al. 1995). Like IFN-γ and TNF-α, MIP-1α down-regulates the
proliferation of hematopoietic progenitor cells (Moore 1991). Karpus and Kennedy found
that anti-MIP-1α treatment prevented the occurrence of acute experimental autoimmune
encephalitis (Karpus and Kennedy 1997). Since minocycline decreased both MIP-1α and
MCP-1 production, it may aid in repression of inflammation that occurs after radiation
insult.
KC, a chemokine that attracts neutrophils and monocytes, has been reported to
increase in response to radiation (Ao, Zhao et al. 2009). Recent studies have shown that it
can be produced by pulmonary fibroblasts in response to radiation and thus may be
utilized as a marker of radiation-induced lung injury (Ao, Zhao et al. 2009). Monocytes,
lymphocytes, keratinocytes and endothelial cells produce IP-10 in response to IFN-γ
(Cassatella, Gasperini et al. 1997). As with many of the other cytokines in this group, IP10 inhibits early hematopoietic progenitors (Sarris, Broxmeyer et al. 1993). It can also
inhibit the actions of GM-CSF (Aronica, Mantel et al. 1995). Finally, IP-10 has been
implicated in radiation-induced lung fibrosis (Keane, Arenberg et al. 1997).
In contrast to the first 6 cytokines in Group II, the impact of radiation on IL-7, IL12(p70) and VEGF was minimal (albeit significant for both IL-7 and VEGF), while
minocycline caused significant decreases in most groups of mice. IL-7 is produced by
stromal cells in the bone marrow, spleen, thymus and gut (van Roon, Glaudemans et al.
2003) and is important for development of B and T cells (Akashi, Kondo et al. 1998).
Administration of IL-7 to patients with metastatic melanoma or sarcoma has decreased
the number of CD4+CD25+Foxp3+ Treg cells (Rosenberg, Sportes et al. 2006). The Treg
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cells contain inflammation and prevent carcinogenesis by reducing cellular damage and
cell proliferation (Zamarron and Chen 2011). It has also been reported that naturally
occurring Treg cells secrete high amounts of thioredoxin which confers increased
tolerance to oxidative stress (Mougiakakos, Johansson et al. 2011). However, IL-7 has
also been reported to promote development of T-cell lymphoma and acute lymphoblastic
leukemia (Or, Abdul-Hai et al. 1998). Thus, the very low level of IL-7 in the minocycline
groups suggests that risk for these types of malignancies may be decreased by the drug.
IL-12 is produced by dendritic cells, macrophages and B cells (Heufler, Koch et
al. 1996). Golab et al. found that this cytokine has myelosuppressive properties and slows
down hematopoiesis in the bone marrow (Golab, Stoklosa et al. 1998). Although IL-12
promotes hematopoiesis in the spleen, this does not fully compensate for its depressive
effect on cells in the bone marrow (Sarris, Broxmeyer et al. 1993). Also, since IL-12
induces the production of IFN-γ by Th1 cells (Robertson and Ritz 1996), the low IL-12
levels correlate well with the reduced IFN-γ levels seen in our study.
VEGF is typically produced by endothelial cells, platelets and macrophages
(Helotera and Alitalo 2007; Duffy A.M., Bouchier-Hayes D. J. et al. 2012). Previous
researchers have shown that levels of this cytokine tend to increase after radiation
exposure (Park, Qiao et al. 2001). VEGF is a potent promoter of angiogenesis and helps
to facilitate tumor growth. Thus, the minocycline-induced reduction in the high VEGF
levels seen in the irradiated groups adds to the potential of this drug for utilization during
cancer radiotherapy.
Like other cytokines in Group II, levels of IL-2 and IL-15 induced by anti-CD3
mAb were generally decreased by minocycline treatment. These findings are consistent
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with reports that the drug inhibits T cell activation (Giuliani, Hader et al. 2005). IL-2 is
produced by T lymphocytes while activated splenic dendritic cells can produce IL-15 in
response to IFN-γ (Mattei, Schiavoni et al. 2001), the latter being a product of activated
Th1 cells. Venkatraman et al. have reported that radiation causes increased production
and decreased utilization of IL-2 by mononuclear cells (Venkataraman and Westerman
1990). Thus, suppression of T cell activation by minocycline is a likely explanation for
reduced IL-2 and IL-15 levels. However, unlike all of the other cytokines in Group II, IL2 and IL-15 levels generally decreased with increasing radiation dose. This is consistent
with the low T cell proportions in the irradiated groups. These two cytokines share many
biological properties such as promotion of T cell proliferation and NK cell development.
However, while IL-15 is primarily implicated in inflammatory diseases, IL-2 can both
promote and control inflammation (Hoyer, Dooms et al. 2008).

Conclusions
In summary, our data demonstrate that treatment with minocycline modulates
capacity to produce cytokines related to hematopoiesis in irradiated and non-irradiated
mice. The drug also counteracted radiation-induced declines in certain cell populations,
especially monocytes/macrophages, granulocytes, NK cells, T cells and CD8+ T cells in
the spleen. Protection of these cell populations can be attributed to the cytokine pattern
obtained, with special emphasis on increased G-CSF, GM-CSF, IL-1α, IL-1β levels and
decreased IFN-γ, TNF-α, MIP-1α, IL-12(p70) and IL-15 levels. Minocycline upregulated both pro- and anti-inflammatory cytokines/chemokines and cell populations
that could promote, as well as contain, inflammation. This implies that the drug may be
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balancing the radiation-induced inflammatory response from getting out of control, while
simultaneously enhancing the body’s capacity to maintain innate and adaptive immune
cell types. Overall, the results do indicate that minocycline up-regulates production
capacity for several cytokines that have been strongly implicated in myelorestoration.
The findings also suggest that the drug may be utilized to speed up hematopoietic
recovery post-irradiation. Further testing of minocycline should be carried out to confirm
its potential as a countermeasure against ARS and as an addition during cancer
radiotherapy.
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Abstract
This study was undertaken to determine if minocycline treatment close to the time
of whole-body irradiation has a prolonged effect on immune parameters. C57BL/6 mice
were treated with minocycline intraperitoneally for 5 days beginning immediately before
irradiation with 1, 2 and 3 Gy 60Co gamma-rays in a single fraction. Spleen, blood and
plasma were collected on day 32 post-exposure. Cell populations were determined in the
blood and spleen. Splenic T cells were activated with anti-CD3 monoclonal antibody and
supernatants were collected after 48 h. Cytokines were quantified in spleen supernatants
and plasma. A number of parameters were significantly (P<0.05) affected at this
relatively late time point of assessment post-irradiation. While radiation resulted in
significantly lower B cell counts at 3 Gy in both blood and spleen, minocycline treatment
increased the counts and/or percentages of splenic B cells at 2 Gy and 3 Gy. In spleen
supernatants, the drug alone significantly increased the levels of cytokines including
interleukin-1α (IL-1α) and IL-6 that are radioprotective, as well as granulocytemacrophage colony stimulating factor (GM-CSF) and G-CSF that accelerate neutrophil
recovery. In addition, minocycline suppressed the production of certain cytokines that
could prevent hematopoiesis, e.g. interferon-γ. Overall, the data suggest that minocycline
exerts a relatively long-term effect on certain cell populations and cytokine production
capacity. Further testing of this drug as a countermeasure for Acute Radiation Syndrome
is necessary to realize its full potential.
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Introduction
Exposure to ionizing radiation is increasingly common in a variety of settings
including space exploration, diagnostic medical procedures and radiotherapy.
Unfortunately, the risks for exposure during military combat or due to acts of terrorism
are also on the rise. Indeed, the September 11, 2001 attack on the United States, as well
as the 2011 disaster at the Fukushima-Daiichi power plant in Japan, have certainly
increased worldwide concern regarding radiation effects on human health. There is
increasing concern also in occupational settings. For example, astronauts on space
missions can get exposed to radiation doses within the range of 1-3 Gy during a solar
particle event (SPE); solar activity is expected to once again reach a maximum in 2013.
Given the health risks associated with exposure, there is an urgent need for safe and
effective normal tissue radioprotectants and radiomitigators.
Radiation can cause a variety of physiological changes collectively referred to as
Acute Radiation Syndrome (ARS). The hematopoietic system is most sensitive to
radiation (Dorr and Meineke 2011) and one of the early manifestations of ARS is the
hematopoietic syndrome. Indeed, declines in circulating white blood cell (WBC),
lymphocyte, platelet and red blood cell (RBC) counts are indicative of hematopoietic
syndrome which can occur upon exposure to total-body radiation doses as low as 1-2
Gray (Gy). Management of hematopoietic syndrome includes administration of colonystimulating factors that promote granulocyte and macrophage regeneration (G-CSF, GMCSF), blood products like erythrocyte concentrate and hematopoietic stem cell
transplantation (HSCT), depending upon the severity of the case (Dainiak 2010). Clinical
management of radiation injury also includes administration of antibiotics, e.g.,
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fluoroquinolones with broad-spectrum activity, to minimize risk for systemic infections
and facilitate recovery of tissues such as bone marrow and gastrointestinal tract (Thomas,
Storb et al. 1976; Vriesendorp, Chu et al. 1994). However, administration of
antimicrobials, as well as antiemetics, antidiarrheal agents and analgesics, is considered
primarily as supportive care.
Evidence in the literature suggests that tetracyclines can be robust radioprotectors of
the hematopoietic system with potential utility in radiation emergencies and anticancer
radiotherapy. Minocycine is a widely used semisynthetic, second generation tetracycline
derivative with broad-spectrum activity and long half-life after administration. Studies
indicate that minocycline has properties that are completely distinct from its
antimicrobial action. It has anti-inflammatory, anti-apoptotic, neuroprotective (Stirling,
Koochesfahani et al. 2005), and free radical scavenging effects (Kraus, Pasieczny et al.
2005) and also possesses anti-tumorigenic potential (Teicher, Dupuis et al. 1995). Given
the properties of minocycline, we hypothesized that it would facilitate regeneration of
immune cell populations following whole-body irradiation and thus have potential to
minimize serious complications associated with ARS. Our previous results obtained at
day 4 post-irradiation were very promising (manuscript accepted for publication). In the
present study, we chose day 32 post-irradiation as our time point because recovery of
immune cell parameters is close to normal at this time following the radiation doses used
in our study. The goal was to determine if minocycline had a long-term effect, as opposed
to a transient/short-lived effect, on the assessed parameters.
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Materials and Methods
Animals and Experimental Design
Female C57BL/6 mice (n = 80; 8-9 weeks of age; Charles River Breeding
Laboratories, Inc. Hollister, CA) were acclimatized for 5-7 days in large plastic cages
(n=10/cage) under standard vivarium conditions. Animals were assigned to 8 group, each
consisting of 10 mice: a) deionized water (dH20) + 0 Gy; b) dH2O + 1Gy; c) dH2O + 2
Gy; d) dH2O + 3 Gy; e) Minocycline + 0 Gy; f) Minocycline + 1 Gy; g) Minocycline + 2
Gy; and h) Minocycline + 3 Gy. Animals were rapidly sacrificed on day 32 postirradiation using 100% CO2 in compliance with the recommendations of the National
Institutes of Health and the Panel of Euthanasia of the American Veterinary Medical
Association. The study was approved by the Loma Linda University Institutional Animal
Care and Use Committee prior to initiation.

Drug Treatment and Irradiation
Minocycline hydrochloride was purchased from Triax Pharmaceuticals, LLC,
Cranford, NJ. Animals in the respective treatment groups received an injection of the
drug (45mg/kg in a volume of 0.1 ml) or an equivalent volume of dH2O, intraperitoneally
(i.p.) immediately before irradiation. A retired Co-60 therapy unit was used to administer
whole-body γ-radiation at a dose rate of 1.58 Gy/min for a total dose of 1, 2 or 3 Gy.
Rectangular plastic aerated cubicles (30 x 30 x 85 mm3) were used to immobilize each
non-anesthetized mouse during exposure. A second injection of minocycline (45mg/kg)
or dH2O was administered to the appropriate groups immediately after irradiation,
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followed by three injections of minocycline (22.5 mg/kg) or dH2O on three consecutive
days post-irradiation. The sham-irradiated groups were given similar treatment.

Blood and Spleen Collection
Cardiac puncture was performed immediately after euthanasia to collect blood in
1 ml tuberculin syringes containing [K2]EDTA. Spleens were harvested and processed
into single-celled suspensions in complete RPMI 1640 medium (Irvine Scientific, Santa
Ana, CA) using sterile applicator sticks. Washing and centrifugation of the spleens was
carried out to remove the debris, followed by lysis of RBC using 2 ml lysis buffer for 4
min at 4˚C. Splenic leukocytes were suspended in 2 ml of RPMI 1640 medium and
whole blood samples were then analyzed for various cell populations as described below.

Body and Relative Spleen Mass (RSM)
Each mouse was weighed at the time of euthanasia and the spleens were weighed
immediately after excision. The following formula was used to calculate relative spleen
mass: RSM = spleen mass (mg)/body mass (g).

Analysis of White Blood Cells (WBC) in Blood and Spleen
An automated analyzer (HESKATM Vet ABC- Diff Hematology Analyzer,
HESKA Corp., Waukesha, WI) was used to quantify WBC and major leukocyte
populations in blood and spleen. Total WBC counts, as well as numbers and percentages
of lymphocytes, granulocytes, and monocytes/macrophages were obtained. Although the
spleen contains a reservoir of monocytes, in addition to macrophages (Swirski,

67

Nahrendorf et al. 2009), cells of this lineage within this body compartment are
collectively referred to as macrophages hereafter for the sake of simplicity. Additional
values were obtained for blood as follows: platelet (PLT) counts, mean platelet volume
(MPV), hematocrit (HCT), mean corpuscular hemoglobin (MCH), mean corpuscular
HGB concentration (MCHC), mean corpuscular volume (MCV), RBC counts, RBC
distribution width (RDW), and hemoglobin (HGB).

Flow Cytometry Analysis of Lymphocyte Populations in Blood and
Spleen
The percentages of specific lymphocyte populations in the blood and spleen were
determined using 2-tube monoclonal antibody (mAb) mixtures purchased from
Pharmingen, San Diego, CA as previously described (Kajioka, Gheorghe et al. 1999). T
regulatory (Treg) cell analysis was carried out with a staining kit which included FJK16s*PE (anti-Foxp3), CD4*FITC, and CD25*APC (eBioscience, Inc., San Diego, CA).
The CD4 CD25 T cells, both with and without Foxp3, were quantified by gating on side
+

+

scatter and the CD4 cells, followed by analysis of the CD25 versus FJK-16s (Foxp3 )
+

+

+

+

subset.

Splenocyte Activation Using Anti-CD3 mAb
The splenocytes were quantified after lysis of RBC using an automated
hematology analyzer (HESKA Corp.). After concentration was adjusted to 2 x 106
cells/ml with complete RPMI 1640 medium, the cells were dispensed into 96-well plates
coated with immobilized anti-CD3 mAb (Mouse Anti-CD3 T-Cell Activation Plates, BD
Pharmingen, San Diego, CA). Each well contained 4 x 105 cells in 0.2 ml of medium.
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After a 48 h incubation at 37oC in a humidified chamber, the supernatants were harvested
and stored in -80˚C until further analysis.

Cytokine Analysis
Immediately after thawing, spleen supernatants were analyzed using the Mouse
Cytokine/Chemokine Milliplex MAP Kit purchased from Millipore, Billerca, MA. The
22 cytokines/chemokines were: interleukin-1α (IL-1α), IL-1β, IL-4, IL-5, IL-6, IL-7, IL9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, G-CSF, GM-CSF, interferon-γ (IFN−γ), IFN-γinduced protein 10 (IP-10), keratinocyte chemoattractant (KC), monocyte chemotactic
protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), regulated upon
activation, normal T-cell expressed and secreted (RANTES) and tumor necrosis factor-α
(TNF-α). In order to quantify vascular endothelial growth factor (VEGF), an enzymelinked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN) was used.

Statistical Analysis
The data were analyzed using SigmaStatTM software, version 2.03 (SPSS Inc.,
Chicago, IL) Two-way analysis of variance (ANOVA) and, when indicated, Tukey’s test
was done to obtain pair-wise multiple comparisons. The data are presented as means and
standard errors of means (SEM). P values less than 0.05 were selected to indicate
significance.
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Results
Body and Relative Spleen Mass (RSM)
Overall, the values for body mass ranged from 22.34±0.25 g (Minocycline + 0
Gy) to 21.2 ± 0.2 g (dH2O + 3 Gy). No statistical difference in RSM was observed
regardless of minocycline treatment or irradiation. RSM ranged from 3.6 ± 0.2 (dH20 + 3
Gy) to 4.2 ± 0.2 (Minocycline + 0 Gy).

WBC and Leukocyte Populations in Blood
As shown in Figure 3.1, the WBC count ranged from 3.3 x 103/mm3 to 4.9 x
103/mm3. Radiation had a main effect on the WBC counts due to decreasing counts with
increasing dose. In post-hoc analysis, significantly low WBC counts were found at 3 Gy
in both drug-treated and untreated groups (P<0.05). Numbers for lymphocytes,
monocytes and granulocytes were generally reduced (P<0.05) after exposure to radiation
and addition of the drug did not have a significant impact (Figure. 3.1).
Although radiation had a main effect on both monocytes and granulocyte
percentages (P<0.05), post-hoc analysis indicated this was due only to increases noted at
the higher doses. These proportional changes were reversed in lymphocytes. Addition of
minocycline brought the lymphocyte percentages close to normal in the 3 Gy group, i.e.,
minimizing the decrease that was caused by radiation alone. Similarly, the drug brought
the monocyte percentage close to normal at 3 Gy, preventing the radiation-induced
increase. The drug increased the granulocyte percentage only at 2 Gy while radiation
increased the granulocyte percentage only at 3 Gy (P<0.05). This resulted in a drug x
radiation interaction for granulocytes (P<0.05).
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FIGURE. 3.1. Major Leukocyte Populations in Blood. An automated hematology
analyzer was used to obtain data for n = 9-10 mice/group. Each bar represents the mean ±
SEM. Two-way ANOVA: §, P<0.05 for main effect of radiation; ‡, P<0.05 for drug x
radiation interaction, Tukey test: *, P<0.05 for dH2O vs Minocycline within each
radiation dose; a, P<0.05 vs 0 Gy within dH2O groups; b, P<0.05 vs 0 Gy within
Minocycline groups.
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PLT and RBC Characteristics in Blood
The results of thrombocyte and erythrocyte characteristics are listed in Table 3.1.
Radiation generally decreased the PLT counts and increased MPV (P<0.05). Although
the changes primarily occurred in the 2 Gy and 3 Gy groups, there were no significant
radiation-dependent differences in post-hoc comparisons between individual groups.
Similarly, although the drug also had a significant impact on the PLT counts (P<0.05),
this effect only reached significance in the 3 Gy groups (P<0.05) and there were no
significant drug x radiation interactions.
Radiation had main effects on RBC counts and HCT, generally decreasing both of
these parameters in irradiated groups (P<0.05). There was no effect of radiation on HGB
and no drug effect or interactions for RBC, HCT and HGB. Although radiation increased
MCV (P<0.05) post-hoc analysis showed no differences between groups. The drugtreated groups generally had lower MCV with significant differences at 3 Gy. However,
this is likely due to the artificially low significant error in the 3 Gy minocycline treated
group. The low error is because all the data for that group was equivalent to 46 because
the machine only gives out integers. Although there was no radiation or drug effect on
MCH, a drug x radiation interaction existed. This interaction was likely due to increase of
MCH at 3 Gy in the non-drug treated group and a subsequent decrease in its 3 Gy drugtreated counterpart. Neither drug nor radiation affected the MCHC. Radiation generally
increased RDW (P<0.05); post-hoc analysis showed that the 1 Gy and 3 Gy groups
(without drug) had higher values compared to 0 Gy (P<0.05). The drug had a main effect
on RDW (P<0.05); post-hoc testing showed that the 3 Gy group treated with minocycline
had higher RDW compared to the 0 Gy group treated with the drug.
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Table 3.1. Summary of Platelet and Erythrocyte Characteristics in Blood. The data were
obtained using an automated hematology analyzer (n = 8-10 mice/group). Mino:
Minocycline. Two-way ANOVA: §, P<0.05 for main effect of radiation; †, P<0.05 for
main effect of drug; ‡, P<0.05 for drug x radiation interaction. Tukey test (within dH2O
or Minocycline): *, P<0.05 dH2O vs. Minocycline within each radiation dose; a, P<0.05
vs. 0 Gy within dH2O groups.
Dose
PLT
(105/mm3)

dH2O
Mino

0 Gy
845.4±11.8
799.8±18.0

MPV§ (μm3)

dH2O
Mino

5.2±0.05
5.3±0.03

5.1±0.02
5.2±0.04

5.2±0.03
5.4±0.05*

5.4±0.1
5.4±0.02

RBC§
(106/mm3)

dH2O

9.0±0.1
8.7±0.2

8.2±0.2a
8.5±0.2

8.5±0.2
8.6±0.2

8.3±0.1a
8.3±0.2

HGB (g/dl)

Mino
dH2O
Mino

13.6±0.1
13.0±0.2

12.6±0.4
13.0±0.3

13.0±0.1
13.0±0.3

13.0±0.2
13.0±0.2

HCT§ (%)

dH2O
Mino

41.1±0.3
40.0±0.3

37.2±0.5
37.2±0.6

33.8±0.7
33.0±1.1

30.8±1.3
31.8±1.1

MCV§ (μm3)

dH2O
Mino

45.60±0.16
46.00±0.21

46.30±0.30
46.00±0.00

45.89±0.20
46.30±0.15

46.70±0.21
46.00±0.00*

MCH‡ (pg)

dH2O
Mino

15.1±0.1
15.3±0.1

15.3±0.1
15.3±0.1

15.2±0.1
15.5±0.1

15.4±0.2
15.1±0.1

MCHC (g/dl)

dH2O
Mino

33.1±0.2
33.0±0.2

33.0±0.3
33.0±0.01

33.0±0.2
33.0±0.2

33.0±0.2
33.0±0.01

RDW§† (%)

dH2O
Mino

14.4±0.1
14.4±0.1

14.8±0.1a
14.7±0.1

14.7±0.1
14.6±0.1

15.0±0.1a
14.8±0.1*

§†

1 Gy
612.0±36.7
639.9±19.6

2 Gy
615.9±20.8
570.6±17.0

3 Gy
626.6±15.6
546.5±14.7*
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WBC and Leukocyte Populations in Spleen
Figure 3.2 shows that the WBC counts in the spleen ranged from 38.3 x 103/mm3
to 49.9 x 103/mm3. Radiation had a main effect on the counts (P<0.05), causing a gradual
decline with increasing dose, but significantly lower WBC counts were present only in
the dH2O + 3 Gy group compared to the dH2O + 1 Gy group (P<0.05) in post-hoc
analysis. The distribution of lymphocytes, macrophages and granulocytes is also shown
in Figure 3.2. Radiation generally caused a decline in lymphocyte counts, resulting in a
significant main effect (P<0.05), although this did not reach significance in post-hoc
analysis. There were no significant drug effects or interactions on the number of
lymphocytes. Although the lymphocyte percentages decreased significantly at 0 Gy in the
presence of minocycline (P<0.05), this effect did not result in significant main effects or
interactions. The macrophage and granulocyte counts were not significantly altered by
radiation or drug. In contrast to lymphocytes and granulocytes, radiation at 3 Gy did
increase macrophage percentages, resulting in a significant main effect (P<0.05).
Granulocyte percentages were unaffected by either radiation or drug.
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FIGURE. 3.2. Major Leukocyte Populations in Spleen. An automated hematology
analyzer was used to obtain data for n = 9-10 mice/group. Each bar represents the mean ±
SEM. Two-way ANOVA: §, P<0.05 for main effect of radiation; Tukey test: *, P<0.05
for dH2O vs Minocycline within each radiation dose; a, P<0.05 vs 0 Gy within dH2O
groups.
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Flow Cytometric Analysis of Lymphocyte Populations in Blood
Radiation generally caused a decline in the circulating T, B and CD8+ Tc cell
counts (Figure. 3.3), resulting in a significant main impact of radiation (P<0.05).
Addition of the drug had no effect based on two-way ANOVA. However, post-hoc
analysis showed that T and B cell counts were no longer depressed in the 3 Gy group that
received minocycline. Although radiation generally decreased the CD4+ Th cell counts
(trend, P<0.1), no significance was obtained in post-hoc analysis. The CD4:CD8 ratio
generally increased with increasing radiation doses (P<0.05). The NK cell counts were
not significantly affected by either drug or radiation. In terms of percentages (Figure.
3.4), radiation alone decreased the levels of B and Tc cells (P<0.05). Post-hoc analysis,
however, revealed that the percentage of B cells in the 3 Gy group was closer to normal
when minocycline treatment was added. T and NK cell percentages were not significantly
altered by radiation. Percentages of Th cells generally increased with increasing radiation
dose, but there was no significant impact of drug.

78

dH2O
Minocycline

3

0.4
0.5

2D Graph 1

0.2
0.0
0.8

D) Tc Cells§

C) B Cells§

0.6
2.0

a

1.5

a

a

1.0

a

a

0.5
0.0
0.4

0.2

0.0

E) NK Cells

F) CD4:CD8 Ratio
a

3

Counts (10 /mm )

0.4

0.3

§

2.5

b

2.0

3

a
1.5

0.2

1.0
0.1
0.5

Counts (103/mm3)

2.5

a

a

3

3

0.6

a

1.0

0.0
3.0

Counts (10 /mm )

0.8

3

3

1.5

Counts (10 /mm )

B) Th Cells

Counts (103/mm3)

A) T Cells

1.0

*

§

3

Counts (10 /mm )

2.0

0.0

0.0

0 Gy

1 Gy

2 Gy

3 Gy

0 Gy

1 Gy

2 Gy

3 Gy

Radiation

Figure. 3.3. Lymphocyte Population Counts in Blood. The data for n = 8-10 mice/group
are based on fluorescence-labeled monoclonal antibodies and flow cytometry. Each bar
represents the mean ± SEM. Two-way ANOVA: §, P<0.05 for main effect of radiation.
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Flow Cytometric Analysis of Lymphocyte Populations in Spleen
Radiation had no significant impact on T, B, NK cell counts (Figure. 3.5). While
there was no significant main effect of drug on T cell counts, they were significantly
reduced in the 1 Gy minocycline-treated group compared to 1 Gy alone (P<0.05) in posthoc analysis. A significant drug x radiation interaction was present for B cells (P<0.05).
This was due to the fact that radiation significantly decreased the B cell counts at 3 Gy
(P<0.05), but not when minocycline treatment was included. While radiation had no main
effect on NK cell count, the cells were significantly reduced at 2 Gy in the drug-treated
group compared to 2 Gy alone (P<0.05). Radiation also did not have a significant effect
on the CD4+ Th or CD8+ Tc cell counts (Figure. 3.5). However, minocycline significantly
decreased the counts for both of these subsets at 1 Gy (P<0.05 vs. the counterpart groups
without drug). A main effect of radiation was seen on the CD4:CD8 ratio which
significantly increased with increasing radiation dose (P<0.05). Addition of minocycline
did not alter this increase.
When looking at the percentages (Figure. 3.6), radiation generally increased the
level of T cells. Addition of minocycline reversed the radiation effect at 2 and 3 Gy,
resulting in a significant drug x radiation interaction (P<0.05). Minocycline caused a
significant proportional increase in B cells at 2 Gy and 3 Gy (P<0.05 vs. the respective
irradiated groups that did not receive drug), resulting in a significant main effect of the
drug (P<0.05) and a drug x radiation interaction (P<0.05). The NK cell percentages were
significantly reduced in the presence of minocycline at 2 Gy (P<0.05). Radiation caused
an increase in Th cell and a decrease in Tc cell percentages (P<0.05). Addition of
minocycline reversed the radiation response in Th cell percentages at 3 Gy, resulting in a
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main effect of drug and a drug x radiation interaction (P<0.05). Tc percentages were
significantly reduced at both 2 Gy and 3 Gy alone compared to both 0 Gy control groups
and to their drug-treated counterparts, resulting in a main effect of drug (P<0.05).
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Figure. 3.5. Lymphocyte Population Counts in Spleen. The data for 5-10 mice/group are
based on fluorescence-labeled monoclonal antibodies and flow cytometry. Each bar
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P<0.05 for main effect of drug; ‡, P<0.05 for drug x radiation interaction. Tukey test: *,
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Flow Cytometric Analysis of CD4+CD25+Foxp3+ T Cells in Spleen
There was no significant impact of drug or radiation on the counts of either
CD4+CD25+ or CD4+CD25+Foxp3+ T cells (Figure. 3.7). In post-hoc analysis, addition of
minocycline caused a significant increase in the percentage of CD4+CD25+ cells, but only
in the 0 Gy group that did not receive radiation (P>0.05 vs. the 0 Gy group without drug).
This resulted in a significant main effect of drug and a drug x radiation interaction on
CD4+CD25+ T cell percentages (P<0.05). There was also a significant drug-induced
increase in the percentage of CD4+CD25+Foxp3+ cells in the 3 Gy group compared to 3
Gy alone (P<0.05). However, this was not enough to result in any main effects or
interactions.
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Cytokine Analysis in Spleen Supernatants
Concentrations of cytokines that were generally increased in the groups that
received minocycline are presented in Figure 3.8. Minocycline had a main effect on IL-4,
IL-10 and IL-13 whereas radiation had a main effect on IL-4, IL-10 and IP-10 (P<0.05).
A drug x radiation interaction was noted for G-CSF, IL-1α, IL-4, IL-6 and IL-10. In posthoc analysis, minocycline increased the levels of G-CSF, GM-CSF, IL-1α, IL-4, IL-6,
RANTES and IL-13 in only the non-irradiated groups (P<0.05). The drug-induced
enhancement in these seven cytokines was no longer present when combined with
radiation, regardless of dose. Among the drug-treated groups, the levels of IL-4 and IL-6
were significantly lower in all irradiated groups compared to the 0 Gy group that received
minocycline (P<0.05). However, the drug significantly increased the level of IL-10 in
both the 0 Gy and 1 Gy groups compared to their respective counterparts that did not
receive drug (P<0.05). A similar, although less pronounced, drug effect was noted for IL17, i.e., a trend (P<0.1) for an increase was present in the non-irradiated and 1 Gy
irradiated groups.
The cytokines that generally were low in the groups treated with the drug or in
which there was no effect of either drug or radiation are shown in Figure 3.9.
Minocycline alone had a main effect on concentrations of IFN-γ, IL-7, and VEGF,
whereas a main effect of radiation was noted for IL-7, VEGF and MIP-1α (P<0.05).
Post-hoc analysis showed that minocycline treatment resulted in low IFN-γ only when
compared to the non-treated 0 Gy group (P<0.05). IL-7, however, was low in all drugtreated groups, regardless of radiation dose (P<0.05 vs. respective groups without drug).
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The post-hoc analysis showed no significant differences among groups in the levels of
MIP-1α, IL-2, IL-12(p70), KC and TNF-α.
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Figure. 3.8. Quantitative Analysis of G-CSF, GM-CSF, IL-1α, IL-4, IL-6, IP-10,
RANTES, IL-13, IL-10, and IL-17. Data were obtained from supernatants after activation
of splenocytes with anti-CD3 monoclonal antibody. The mean ± SEM is presented for n
= 8-10 mice/group. Two-way ANOVA: §, P<0.05 for main effect of radiation; †, P<0.05
for main effect of drug; ‡, P<0.05 for drug x radiation interaction. Tukey test: *, P<0.05
for dH2O vs Minocycline within each radiation dose; b, P<0.05 vs 0 Gy within
Minocycline groups; T: P<0.1 for dH2O vs Minocycline within each radiation dose.
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Figure. 3.9. Quantitative Analysis of IFN-γ, IL-7, VEGF, MIP-1α, IL-2, IL-12(p70), KC, and
TNF-α. The mean ± SEM is presented for n = 8-10 mice/group. Two-way ANOVA: §, P<0.05
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Discussion
Leukocytes and lymphoid organs are well known to be highly radiosensitive.
Bone marrow failure as a consequence of radiation exposure can result in severe
leukopenia which, in turn, can greatly influence morbidity and mortality (Bodey, Buckley
et al. 1966). The present study focused on the relatively late effects of minocycline on
hematopoietic and immune parameters in an irradiated mouse model, i.e., on day 32 after
exposure. Another goal was to determine if early (day 4) changes in cell profiles and
cytokine production patterns that were noted in our previous study (manuscript in press)
could be used as biomarkers for late changes due to radiation and/or drug treatment. All
aspects of study design in the previous and present studies were identical except for time
point for analyses. Major findings on day 4 post-irradiation were that minocycline
treatment significantly increased counts and/or percentages of splenic macrophages,
granulocytes, total T cells, CD8+ T cells, and NK cells and modified splenocyte capacity
to secrete numerous cytokines in irradiated mice.
In the present study, distribution of most of the major cell types was equivalent to
normal. However, complete restoration of some subpopulations was still lacking. B cell
counts were significantly decreased in both the blood and spleens from the 3 Gy group
(without drug) compared to the non-irradiated group. This contradicts Kajioka et al. who
found that B cell counts in blood after 3 Gy whole-body irradiation of same strain mice
were no longer significantly depressed by day 29 after exposure (Kajioka, Andres et al.
2000). However, it should be noted that the mean value for B cell counts was ~35%
below that of the non-irradiated controls and the mice were stimulated with sheep RBCs
(a procedure that may have enhanced the recovery process in the study by Kajioka et al.).
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In the spleen, minocycline reversed/eliminated the 3 Gy radiation-induced B cell
decrease, thereby suggesting that the drug could be helpful in maintenance/recovery of
this cell type after exposure to a relatively high radiation dose. Although splenic T cell
counts were equivalent to normal, circulating T cells were still low in the 3 Gy groups
that did not receive the drug. Similarly, although CD4+ Th cells recovered in both
compartments (blood and spleen), the CD8+ Tc cell counts at 3 Gy in the blood were
significantly lower compared to the dH2O + 0 Gy group (P<0.05). This is consistent with
the literature where Tc cells are regarded to be more radiosensitive compared to the Th
cell subset (Kajioka, Andres et al. 2000; Wilkins, Kutzner et al. 2002). Interestingly, it
has been proposed that the level of radiation-induced apoptosis in the CD4+ and CD8+ T
cell populations has potential to identify patients who are hypersensitive to radiation, and
thus may be used to help predict risk for development of late toxicities (Ozsahin,
Crompton et al.).
Our previous study in which assessments were conducted on day 4 postirradiation showed that treatment with minocycline increased splenic production capacity
for radioprotective cytokines and growth factors, but suppressed production of cytokines
that could limit hematopoiesis. Results of the present study show that the drug on its own
significantly increased the levels of G-CSF, GM-CSF, IL-1α, IL-4, IL-6, IL-10, IL-13,
and RANTES even at day 32 after irradiation. Although, IL-1α and IL-6 are
radioprotective (Neta 1997) and G-CSF and GM-CSF help in restoring granulocytes after
neutropenia, all of the minocycline-induced increases in these cytokines were no longer
evident in the irradiated groups that had been treated with the drug. In our previous
observations at day 4 post-irradiation, minocycline significantly increased the production
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of these cytokines even in the irradiated groups, suggesting that the impact of the drug on
the cytokines was acute and transient with respect to radiation response. Health
implications, if any, of the changes seen with drug alone at day 32 remain to be
determined.
As noted above, the drug increased the level of IL-10, a Th2 cell-derived antiinflammatory cytokine. There is also evidence that IL-10 can prevent the development of
fibrosis (Zhang, Zheng et al. 2007), which is a late consequence of radiation exposure.
Nelson et al. reported that IL-10 treatment resulted in reduction of inflammation and
fibrosis scores in patients with hepatitis-related liver fibrosis (Nelson, Tu et al. 2003).
The increased levels of IL-10 observed even at day 32 post-irradiation indicate that the
drug may have some benefit in this regard. IL-10 also stimulates humoral immunity
(Munford and Pugin 2001) and inhibits the suppression of hematopoiesis induced by IFN
and TNF-α (Geissler, Kabrna et al. 2002). Other investigators have shown that
minocycline increases the expression of IL-10 mRNA and reduces TNF-α mRNA (Lee,
Yune et al. 2003).
There was a trend for drug-induced enhancement of IL-17 level in spleen
supernatants from the 0 Gy and 1 Gy groups. IL-17, a cytokine secreted by activated
CD4+ and CD8+ T cells, induces the production of hematopoietic cytokines (Fossiez,
Djossou et al. 1996; Hinrichs, Kaiser et al. 2009). It has been shown to stimulate
fibroblast production of IL-6 and G-CSF, both of which assist in hematopoiesis (Xiao,
Leemhuis et al. 1992). These findings related to IL-17 support the possibility that
minocycline may be a useful enhancer of hematopoietic recovery.
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While radiation increased the production of VEGF at 3 Gy (P<0.05 vs 0 Gy),
minocycline suppressed its production at both 1 and 3 Gy. Since VEGF is an angiogenic
cytokine which helps primary tumors to grow and metastasize, treatment with the drug
may limit these possibilities during radiotherapy, as well as in populations with not yet
diagnosed cancer that are exposed to radiation. Recent reports do, indeed, indicate that
minocycline has anti-tumor properties (Markovic, Vinnakota et al. 2011; Pourgholami,
Mekkawy et al. 2012). However, IL-7, which helps in the development of T and B
lymphocytes that have potential to directly or indirectly attack tumor cells, was
significantly down-regulated in all groups that received minocycline. A similar pattern
was observed for this cytokine on day 4 post-irradiation in our previous study. IL-7 is
also known to promote the secretion of Th1 cell-derived pro-inflammatory cytokines
such as IFN-γ and TNF-α and thus perpetuate responses associated with this T cell subset
(van Roon, Glaudemans et al. 2003). Reduced levels of IFN-γ observed in the drugtreated group that received 0 Gy could be due to inadequate activation of Th1 cells.
Minocycline is known to suppress T cell activation (Kloppenburg, Verweij et al. 1995;
Szeto, Pomerantz et al. 2011).

Conclusions
Although minocycline increased several anti-inflammatory, immunosuppressive
cytokines such as IL-4, IL-6, and IL-10 and decreased IFN-γ, it also up-regulated proinflammatory cytokines like G-CSF, GM-CSF, IL-1α, IL-17, and RANTES. Whether it
is beneficial that treatment with the drug increases production capacity in the spleen for
immunosuppressive cytokines on its own even at day 32, remains to be determined. An
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immunosuppressive environment could lessen the ability to fight infections. Kielian et al.
indicated that minocycline has immune modulatory properties that balance deleterious
versus beneficial inflammation (Kielian, Esen et al. 2007). However, the drug also
counteracted radiation-induced declines in the B cell population in the spleen, which
would promote humoral immunity. Overall, the study brings new knowledge on the
properties of minocycline, a drug that has potential as a normal tissue radioprotectant.
Further research should be carried out to determine its effectiveness in human subjects
during cancer radiotherapy and for the management of ARS.
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Abstract
This study was focused on the effects of minocycline, an antibiotic, on mouse
brain and human glioblastoma versus non-tumor cell lines after radiation exposure.
C57BL/6 mice were treated with minocycline intraperitoneally for 5 days beginning
immediately before radiation with 1, 2 and 3 Gy 60Co gamma rays in a single fraction.
Brains were collected on days 4 and 32 post-irradiation. Cytokines were quantified in
supernatants from homogenized brain tissue. Minocycline significantly increased the
levels of interleukin (IL)-10, IL-13, IL-15 and vascular endothelial growth factor (VEGF)
on day 4 in one or more of the irradiated groups compared to radiation alone (P<0.05).
IL-10 and IL-13 are anti-inflammatory, IL-15 can prevent apoptosis and VEGF has
neuroprotective properties. On day 32, the drug decreased the level of IL-1β in the 2 Gy
irradiated group (P<0.05 vs 2 Gy alone); this cytokine is implicated in several immunerelated central nervous system (CNS) pathologies. Microarray analysis of brains on day
32 showed that while radiation increased several inflammatory genes like Il1f10, Il17,
Tnfrsf11b, Tnfsf12, Il12b and Il1f8, these were no longer up-regulated in minocyclinetreated groups. Similarly, pro-apoptotic gene Bik and nitric oxide synthase producer
(Nostrin) were no longer up-regulated in the drug-treated groups. In vitro results showed
that minocycline enhanced the viability of human astrocytes (P<0.05) without increasing
or reducing the viability of human glioblastoma cells. Overall, these data suggest that the
drug could be a useful addition during radiotherapy of CNS malignancies. Further testing
of minocycline as a radioprotectant in an in vivo model of glioblastoma is necessary to
determine its potential application.
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Introduction
Radiation is a major treatment option for tumors located close to or within the
central nervous system (CNS). Eradication of the cancer, however, is accompanied by
damage to normal brain tissue and may impact cognition (Raber, Rola et al. 2004; Butler,
Rapp et al. 2006; Meyers and Brown 2006). It has been estimated that 50% of adult and
100% of pediatric cancer survivors who receive whole-brain irradiation for metastatic
disease will develop cognitive dysfunction (Ramanan, Zhao et al. 2010). Patients who are
subjected to cranial radiotherapy for management of primary and metastatic tumors form
the most severe cases (~200,000/yr) (Abayomi 1996; Ramanan, Zhao et al. 2010).
Neurocognitive deficits are an especially harmful side effect for children who undergo
radiotherapy as a life-saving option. Whole-brain irradiation has also been shown to
impact conditioned taste aversion in rodent models (Rabin and Hunt 1986).
Irradiation of brain tissue often results in inflammation (Moore, Olschowka et al.
2004; Moravan, Olschowka et al. 2011). It is believed that radiation induces a
neuroinflammatory milieu of pro-inflammatory cytokines and other factors, resulting in
prolongation of oxidative stress initiated by radiation. This, in turn, is responsible for the
pathogenesis of radiation-induced brain injury (Rola, Fishman et al. 2008; Ramanan,
Zhao et al. 2010). An acute response to radiation in the brain involves an increase in
inflammatory cytokines and mediators such as tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β), intercellular adhesion molecule 1 (ICAM-1) and cyclooxgenase-2
(COX-2), as well as activation of transcription factors such as nuclear factor kappa-lightchain-enhancer of activated B cells (NF-kB) and activator protein 1 (AP-1) (Hong,
Chiang et al. 1995; Raju, Gumin et al. 1999; Raju, Gumin et al. 2000).
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Irradiation of the brain can also lead to apoptosis in the neural stem cell pools in
the hippocampus, a structure critical to memory and other behaviors (Reh 2002;
Bálentová, Hajtmanová et al. 2011). Indeed, radiation-induced decrements in stem cell
populations has been shown to impact behavior in animal models(Kempermann, Kuhn et
al. 1997; van Praag, Christie et al. 1999).
Minocycline, a tetracycline derivative, has been reported to be neuroprotective,
anti-apoptotic, anti-tumorogenic and anti-inflammatory by several researchers (Markovic,
Vinnakota et al. 2011). Markovic et al. also reported its potential in preventing the spread
of glioma cells (Markovic, Vinnakota et al. 2011). The purpose of this study was to
determine the efficacy of minocycline as an anti-inflammatory radioprotectant by
characterizing the brain cytokine microenvironment in an animal model. In addition, we
also verified the effects of minocycline on the radiation response in five different cell
lines: three human glioblastoma cell lines and two “normal” cell lines (human astrocytes
and microglia).

Materials and Methods
Animals and Experimental Design
Female C57BL/6 mice (n = 80; 8-9 weeks of age; Charles River Breeding
Laboratories, Inc. Hollister, CA) were acclimatized for 5-7 days in large plastic cages
(n=10/cage) and under standard vivarium conditions. Animals were assigned to 8 groups
(10 mice/group): (a) deionized water (dH20) + 0 Gy (b) dH2O + 1Gy; (c) dH2O + 2 Gy;
(d) dH2O + 3 Gy; (e) Minocycline + 0 Gy; (f) Minocycline + 1 Gy; (g) Minocycline + 2
Gy; and (h) Minocycline + 3 Gy. Animals were rapidly sacrificed on days 4 and 32 post-
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irradiation using 100% CO2 in compliance with the recommendations of the National
Institutes of Health and the Panel of Euthanasia of the American Veterinary Medical
Association. All procedures were approved by the Institutional Animal Care and Use
Committee of Loma Linda University.

Drug Treatment and Irradiation
Minocycline was purchased from Triax Pharmaceuticals, LLC, Cranford, NJ.
Animals in the respective treatment groups were administered an injection of
minocycline hydrochloride (45mg/kg in a volume of 0.1 ml) intraperitonealy (i.p.) or
dH2O immediately before irradiation. A Co-60 source was used to administer whole-body
radiation at a dose rate of 1.58 Gy/min for a total dose of 1, 2 or 3 Gy. Rectangular plastic
aerated boxes (30 x 30 x 60 mm3) were used to place non-anesthetized mice individually.
A second injection of minocycline (45mg/kg) or dH2O was administered to the
appropriate groups immediately after irradiation. Three consecutive injections of
minocycline (22.5 mg/kg) or dH2O were administered on the following three days postirradiation. The sham-irradiated groups were given similar treatment, but without the
radiation.

Brain Collection
Brains were collected following euthanasia and immediately snap frozen in liquid
nitrogen. Brain homogenates were prepared using phosphate buffered saline (PBS
without calcium and magnesium) containing a cocktail of protease inhibitor tablets from
Hoffman-La Roche, Inc. (Pleasanton, CA) and 0.05% Tween-20. One ml of buffer
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solution was used for every 0.2 gm tissue for homogenization followed by centrifugation.
The supernatants were stored at -80˚C until further analysis.

Cytokine Analysis
Brain supernatants from -80˚C were thawed and analyzed for 22 different
cytokines and chemokines using the Mouse Cytokine/Chemokine Milliplex MAP Kit
(Millipore, MA) and analyzed with the Luminex100 (Linco Research, Inc., St. Charles,
MO) as per the manufacture’s instructions. The cytokines/chemokines evaluated were as
follows: IL-1α, IL-1β, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL17, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage (GM)-CSF,
interferon-γ (IFN−γ), IFN-γ-induced protein 10 (IP-10), keratinocyte chemoattractant
(KC), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α
(MIP-1α), regulated upon activation, normal T-cell expressed and secreted (RANTES)
and TNF-α. Vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9
(MMP-9) were analyzed via enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems, Minneapolis, MN) as per the manufacturer’s instructions.

Microarray Analysis of Cytokine and Neurotoxicity Gene Expression
in Brain
Expression of cytokine- and neurotoxicty-related genes was determined using
quantitative real-time polymerase chain reaction (qRT-PCR). The PAMM-21 Mouse
Cytokine and PAMM-96 Mouse Neurotoxicity gene arrays were purchased from SABiosciences, Frederick, MD. Standard procedures were used throughout.
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Cell Lines for In Vitro Study
Three human glioblastoma cells lines were purchased from American Type
Culture Collection (ATCC) for the study: A172, T98G and U87MG. All three cell lines
have a mutation in the phosphatase and tensin homolog (PTEN) gene while T98G also
has a point mutation in exon 7 of the TP53 gene. Human astrocytes and human microglia
were purchased from ScienCell Research Laboratories (Carlsbad, CA). The tumor cells
were cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM) with 5% fetal bovine
serum (FBS) and 5% Penicillin-Streptomycin. Cell line specific growth media from
ScienCell were used for astrocytes and microglia. Cells were maintained at 37˚C and 5%
CO2. Tumor cells that were analyzed were within 12-15 passages and non-tumor cells
were analyzed within 7-8 passages from the time of arrival.

Tritiated Thymidine (3H-TdR) Incorporation Assay
Cells were harvested, washed, re-suspended and counted manually using trypan
blue, to obtain viable cells, and the cell concentration was adjusted to 1x105 cells/ml.
Aliquots (100 μl) of single-celled suspensions were dispensed into flat-bottom wells of
96-well plates and allowed to establish overnight. Minocycline at concentrations of 0, 1,
2 or 4 μM was added 2 h prior to irradiation in replicates of four. Equal amount of the
appropriate medium was added to the wells that did not receive the drug. The cells were
irradiated approximately 24 h after plating at radiation doses of 0, 2, 4, 6 and 8 Gy using
Co-60 γ rays. Four hours prior to each time point of cell harvest, 3H-TdR (specific
activity = 46 Ci/mmol; ICN Radiochemicals, Irvine, CA) was added at 1 μCi/50μl/well.
Cells were harvested 24, 48 and 72 h after irradiation with 0.25% trypsin solution and a
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Tomtec multiple-sample harvester (Hamden, CT) onto a single filter paper subdivided
into 96 sections. Each filter paper was sealed in a sample plastic bag with 5 ml of beta
scintillation fluid. The incorporation of radioactivity into cell DNA (counts per minute;
cpm) was then quantified in the Trilux 1450 MicroBeta liquid scintillation counter
(Wallac, Turku, Finland). Three independent experiments were performed.

Cell Viability Assay
To quantify proportional changes in viable cells, we used the Cell Titre Glo
Luminescent Cell Viabiliy assay kit (Promega, Madison, WI) as per the manufacturer’s
instructions. Briefly, cells were grown on 96-well plates in 4 replicates. One-hundred μl
of cells were plated per well at a concentration of 105 cells/ml. Cells were allowed to
grow for 24 h; 25 μl minocycline solution at concentrations of 0, 1, 2 or 4 μM was added
4 h prior to irradiation. Cells were irradiated 24 h after plating using Co-60 γ rays and cell
viability was determined. Assay reagent (125 μl) was added to cells at room temperature,
mixed on a plate shaker and incubated at RT for approximately 30 min. A multimode
plate reader (Infinite M200, TECAN, Durham, NC) was used to read the luminescent
signal. Three independent experiments were performed.

Statistical Analysis
The data were analyzed by two-way analysis of variance (ANOVA). Tukey’s test
was performed for pair-wise multiple comparisons when indicated. Means and standard
errors of means (SEM) are presented here. A P value of <0.05 indicated significance.
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SigmaStatTM software, version 2.03 (SPSS Inc., Chicago, IL) was used to analyze the
data.

Results
Cytokine Analysis
Twelve cytokines were detectable in the multiplex and ELISA analyses on day 4
(Figure. 4.1). There was no significant impact of drug or radiation on IFN-γ, KC, IL-1α.
IL-4, IL-7 and IL-13 The cytokines that were up-regulated in the presence of minocycline
were IL-10, IL-15 and VEGF. There were minocycline-induced increases in IL-10 in all
irradiated groups (P<0.05 vs. counterparts that did not receive drug), causing a main
effect of drug (P<0.05). While radiation generally resulted in lower IL-10 levels with
increasing radiation dose (P<0.05), this response was eliminated or reversed in the drugtreated mice, resulting in a drug x radiation interaction (P<0.05). Radiation did not have
an effect on IL-13 and IL-15. The drug-treated 1 Gy group showed a significant increase
in IL-13 level (P<0.05 vs 1 Gy without drug). In contrast, minocycline generally
increased the level of IL-15, resulting in a main effect (P<0.05). However, this druginduced increase was only significant in post-hoc analysis compared to 1 Gy alone
(P<0.05). Although there was a significant main effect of radiation on IP-10 (P<0.05),
this was primarily due to the relatively high levels noted in both 3 Gy groups, but this did
not reach significance in post-hoc analysis. Similarly, although the drug generally
decreased IP-10 compared to their dH2O-treated counterparts, resulting in main effects of
radiation (P<0.05), there were no drug-induced differences noted in post-hoc analysis.
Radiation generally decreased IL-9 (P<0.05), although significance was found only in 2
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and 3 Gy, dH2O groups that did not receive drug (P<0.05). Addition of minocycline did
not modify this response.
On day 32 after irradiation, 10 cytokines were detectable. However, only two of
these, i.e. IL-1β and IP-10, were significantly affected by either radiation or drug. There
was as a main effect of drug on IL-1β (P<0.05), most likely due to the relatively low
levels at 0 and 2 Gy. This drug effect on IL-1β reached significance in post-hoc analysis
at 2 Gy (P<0.05). Despite this radiation dose-dependent bi-phasic response, there were no
significant main effects or interactions involving radiation for this cytokine. In contrast,
radiation generally increased IP-10 levels, resulting in a main effect of radiation
(P<0.05). However, there were no significant differences among individual groups in
post-hoc analysis. Minocycline did not affect or alter this response.
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Figure. 4.1. Cytokine Analysis on Day 4. Each bar represents the mean ± SEM for n= 4-5
mice/group. Two-way ANOVA: §, P<0.05 for main effect of radiation; †, P<0.05 for
main effect of drug; ‡, P<0.05 for interaction between radiation and minocycline, Tukey
test: *, P<0.05 dH2O vs Minocycline within each radiation dose; a, P<0.05 vs 0 Gy
within dH2O groups; b, P<0.05 vs 0 Gy within Minocycline groups.
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Figure. 4.2. Cytokine Analysis on Day 32. Each bar represents the mean ± SEM for n =
4-5 mice/group. Two-way ANOVA: §, P<0.05 for main effect of radiation; †, P<0.05 for
main effect of drug, Tukey test: *, P<0.05 dH2O vs Minocycline within each radiation
dose.
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Microarray Analysis of Cytokine and Neurotoxicity Gene Expression
in Brain
The results for cytokine and neurotoxicity gene expression are shown in Tables
4.1 and 4.2, respectively. These analyses were performed only on day 32 postirradiation. To be considered significant, the changes in gene expression had to meet the
criteria of P value <0.05 and fold change >1.5 vs 0 Gy dH2O.
Based on results from the cytokine array, radiation alone increased the expression
of Csf2, Ctf1, Il15, Inha, Bmp10, Il11, Il17c, Il20, Tnfrsf11b, Tnfsf12, Gdf1, Ifnb1,
Gdf15, Il12b, Il1f6, Il1f8,Il24, Il1f10, Gdf10, Gdf2, Cd70, Bmp5 and Bmp6 and the drug
alone increased Cd70 and Bmp5 (See Table 3). The combined treatment resulted in a
decrease in Gdf5 and increased Il1rn, Il3, Il1f9, Bmp7, Tnfsf10 and Tnfsf11, while either
radiation or drug alone did not have a significant impact on any of these genes.
Minocycline did not have any effect on radiation-induced increased expression of
Tnfrsf12. In contrast, the drug slightly reduced the radiation-induced increases in Inha,
Gdf1, Gdf15, Il1f6, Il1f8 and Bmp6 and the decrease was more enhanced in Il1f10 and
Gdf2.
Data from the neurotoxicity array showed that radiation increased the expression
of Ereg, Hspa5, Nostrin, Birc2, Txpnip, Atf4, Fas, Bik, Cidea and Pappa, while the drug
increased Tyrp1 (See Table 4). The combined treatment resulted in slight increases in
Birc2 and Txnip expression, while slightly reducing Fas and Cidea. The radiation induced
increases in Ereg, Hspa5, Nostrin, Bik and Pappa were no longer present when
minocycline was added to irradiated groups.
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Table 4.1 Fold Changes in Cytokine Gene Expression in Brain Tissue vs dH2O + 0 Gy
on Day 32 Post-IR (P Value <0.05 and Fold Change >1.5). The data were obtained from
n = 4 mice/group. Radiation alone increased the expression of Csf2, Ctf1, Il15, Inha,
Bmp10, Il11, Il17c, Il20, Tnfrsf11b, Tnfsf12, Gdf1, Ifnb1, Gdf15, Il12b, Il1f6, Il1f8,Il24,
Il1f10, Gdf10, Gdf2, Cd70, Bmp5 and Bmp6 and the drug alone increased Cd70 and
Bmp5. The combined treatment resulted in a decrease in Gdf5 and increased Il1rn, Il3,
Il1f9, Bmp7, Tnfsf10 and Tnfsf11 while radiation or drug did not have any impact on any
of these genes. Minocycline did not have any effect on radiation induced increased
expression of Tnfrsf12. In contrast, the drug slightly reduced the radiation induced
increases in Inha, Gdf1, Gdf15, Il1f6, Il1f8 and Bmp6 and the decrease was more
enhanced in Il1f10 and Gdf2.
Gene

dH2O +
3 Gy

Mino +
0 Gy

Mino +
3Gy

Csf2

1.5

Ctf1
Il15
Inha
Bmp10
Il11
Il17c
Il20

1.6
1.6
1.6
1.7
1.7
1.7
1.7

Tnfrsf11b

1.7

Tnfsf12

1.7

1.7

Gdf1
Ifnb1
Gdf15
Il12b
Il1f6
Il1f8
Il24
Il1f10
Gdf10
Gdf2
Cd70
Bmp5
Bmp6
Gdf5
Il1rn
Il3
Il1f9
Bmp7

1.8
1.8
1.9
1.9
1.9
1.9
1.9
2.1
2.7
2.7
3.3
3.6
8.5

1.7

Colony stimulating factor 2 (granulocytemacrophage)
Cardiotrophin 1
Interleukin 15
Inhibin alpha
Bone morphogenetic protein 10
Interleukin 11
Interleukin 17C
Interleukin 20
Tumor necrosis factor receptor superfamily,
member 11b (osteoprotegerin)
Tumor necrosis factor (ligand) superfamily,
member 12
Growth differentiation factor 1
Interferon beta 1, fibroblast
Growth differentiation factor 15
Interleukin 12B
Interleukin 1 family, member 6
Interleukin 1 family, member 8
Interleukin 24
Interleukin 1 family, member 10
Growth differentiation factor 10
Growth differentiation factor 2
CD70 antigen
Bone morphogenetic protein 5
Bone morphogenetic protein 6
Growth differentiation factor 5
Interleukin 1 receptor antagonist
Interleukin 3
Interleukin 1 family, member 9
Bone morphogenetic protein 7
Tumor necrosis factor (ligand) superfamily,
member 10
Tumor necrosis factor (ligand) superfamily,
member 11

1.5

1.6
1.6
1.8
1.6
1.6
2.1
2.7

3.9
8.4
-2.4
1.6
1.6
1.7
2.4

Tnfsf10

2.4

Tnfsf11

2.7

Gene description
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Table 4.2 Fold Changes in Neurotoxicity Gene Expression in Brain Tissue vs dH2O + 0
Gy on Day 32 Post-IR (P Value <0.05 and Fold Change >1.5). The data were obtained
from n = 4 mice/group. Radiation increased the expression of Ereg, Hspa5, Nostrin,
Birc2, Txpnip, Atf4, Fas, Bik, Cidea and Pappa while the drug increased Tyrp1. The
combined treatment resulted in slight increase in Birc2 and Txnip while slightly reducing
Fas and Cidea.

Gene

dH2O+ Mino
3 Gy +0 Gy

Ereg
Hspa5
Nostrin
Birc2
Txnip
Atf4
Fas
Bik

1.5
1.5
1.5
1.6
1.7
1.8
1.8
1.9

Cidea
Pappa
Tyrp1
Tacr1

1.9
2.0

Mino
+ 3 Gy

1.7
1.8
1.8
1.7

1.6
2.2
1.6

Gene description
Epiregulin
Heat shock protein 5
Nitric oxide synthase trafficker
Baculoviral IAP repeat-containing 2
Thioredoxin interacting protein
Activating transcription factor 4
Fas (TNF receptor superfamily member 6)
Bcl2-interacting killer
Cell death-inducing DNA fragmentation factor, alpha
subunit-like effector A
Pregnancy-associated plasma protein A
Tyrosinase-related protein 1
Tachykinin receptor 1
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DNA Synthesis
There were radiation-induced decreases in tritiated thymidine incorporation in
A172 glioma cells (Figure 4.3) at all three time points of assessment (P<0.05). However,
at 72 h the radiation effect was primarily due to differences between the 2 Gy and 8 Gy
exposures; no individual radiation dose resulted in significant difference when compared
to the 0 Gy control in post-hoc analysis. There were no effects or interactions involving
the drug on this cell line at any time point.
For T98G glioma cells (Figure 4.4), radiation generally reduced DNA synthesis at
all time points (P<0.05). At 24 and 48 h, radiation typically decreased DNA synthesis
with increasing dose of radiation when compared to 0 Gy (P<0.05). However, at 72 h the
decrease occurred only at 8 Gy. There was also a main effect of drug at 24 h (P<0.05),
primarily due to relatively low DNA synthesis in the presence of 4 μM minocycline
(P<0.05).
For U87MG glioma cells (Figure 4.5), both radiation and drug consistently
resulted in reductions in DNA synthesis at each time point (P<0.05). A drug x radiation
interaction was also present at both 24 and 72 h post-exposure. At 24 h, the interaction
was likely due to the anomalous decrease in the cells that were cultured in presence of 1
μM drug and irradiated with 4 Gy. At 72 h, the interaction was likely due to similarly
anomalous increases when the drug was present at 1 μM and 2 μM and radiation was at 0
Gy and 4 Gy, respectively.
The data for the normal human cell lines, HA (astrocytes) and HM (microglia) are
shown in Figures 4.6 and 4.7, respectively. For both of these cell types, radiation and
drug significantly impacted DNA synthesis at each time point (P<0.05). Radiation
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drastically reduced synthesis at all doses, typically plateauing between 2 and 4 Gy for all
time points and in both cell lines. For HA cells, the drug effect at 24 h was due to
decreases regardless of drug concentration compared to 0 μM, although this reached
significance only at the lower radiation doses in post-hoc analysis. At 48 and 72 h, the
drug effect was due to low values when it was present at 1 and 4 μM versus the 0 μM
control. At 72 h, there was no response at 2 Gy and 6 Gy, resulting in a drug x radiation
interaction.
For HM cells, the drug effect at 24 h (P<0.05) was due to decreased DNA
synthesis when the medium contained 2 and 4 μM minocycline compared to 0 μM at 0
Gy. Although the increase noted with 4 μM at 8 Gy was only a trend (P<0.1), this
increase, combined with the decreases noted at 0 Gy, was enough to result in a significant
radiation x drug interaction (P<0.05). At 48 and 72 h, this was due to low values in
medium with 1 and 4 μM compared to the 0 μM control. Again, post-hoc analysis
showed significant differences only at 0 Gy at 48 h and at 0 and 4 Gy at 72 h (P<0.05).
The response at 72 h also resulted in a significant drug x radiation interaction.
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Figure. 4.3. Tritiated Thymidine Incorporation Assay for Glioblastoma Cell Line A172.
Each bar represents the mean ± SEM for n=7-8 samples/group. Two-way ANOVA: §,
P<0.05 for main effect of radiation.

119

CPM (Counts per minute)

T98G§† 24 hrs

50000
40000
30000
20000
10000

2D Graph 1

CPM (Counts per minute)

0

T98G§ 48 hrs

50000
40000
30000
20000
10000
0

CPM (Counts per minute)

X Data

T98G§ 72 hrs

50000
40000
30000

0uM Mino
1uM Mino
2uM Mino
4uM Mino

0uM Mino
1uM Mino
2uM Mino
4uM Mino

20000
10000
0
0 Gy

2 Gy

4 Gy

6 Gy

8 Gy

Figure. 4.4. Tritiated Thymidine Incorporation Assay for Gliobalstoma Cell Line T98G.
Each bar represents the mean ± SEM for n=7-8 samples/group. Two-way ANOVA: §,
P<0.05 for main effect of radiation; †, P<0.05 for main effect of drug.

120

CPM (Counts per minute)

2500

U87MG

§†‡

24 hrs

2000

1500

c
b

1000

500

a

2D Graph 1

0

CPM (Counts per minute)

5000

U87MG

§†

48 hrs

4000

3000

ab
c

2000

1000

0

CPM (Counts per minute)

2500

X Data

U87MG§†‡ 72 hrs
2000

1500

0uM Mino
1uM Mino
2uM Mino
4uM Mino

0uM Mino
1uM Mino
2uM Mino
4uM Mino

1000

c
500

ac
c

0
0 Gy

2 Gy

4 Gy

6 Gy

8 Gy

Figure. 4.5. Tritiated Thymidine Incorporation Assay for Glioblastoma Cell Line
U87MG. Each bar represents the mean ± SEM for n=7-8 samples/group. Two-way
ANOVA: §, P<0.05 for main effect of radiation; Tukey test: a, P<0.05 1μM vs 0μM
Mino within radiation group, b, P<0.05 2μM vs 0μM Mino within radiation group, c,
P<0.05 4μM vs 0μM Mino within radiation group.

121

1800

CPM (Counts per minute)

§†

HA

24 hrs

1600

1400

ab
c

400

200

c

0

CPM (Counts per minute)

2000

HA

48 hrs

1500

a
c
1000

500

0

1500

CPM (Counts per minute)

§†

HA
1000

X Data
§†‡

72 hrs
0uM Mino
1uM Mino
2uM Mino
4uM Mino

0uM Mino
1uM Mino
2uM Mino
c
4uM Mino

500

0

ac

ac

0 Gy

2 Gy

4 Gy

6 Gy

8 Gy

Figure. 4.6. Tritiated Thymidine Incorporation Assay for Human Astrocyte (HA) Cell
Line. Each bar represents the mean ± SEM for n=7-8 samples/group. Two-way ANOVA:
§, P<0.05 for main effect of radiation; ‡, P<0.05 for interaction between radiation and
minocycline. Tukey test: a, P<0.05 1μM vs 0μM Mino within radiation group, b, P<0.05
2μM vs 0μM Mino within radiation group, c, P<0.05 4μM vs 0μM Mino within radiation
group.

122

HM§‡ 24 hrs

CPM (Counts per minute)

2500
2000
1500

0uM Mino
1uM Mino
2uM Mino
4uM Mino

b
c

1000
500

2D Graph 1
0

CPM (Counts per minute)

2500

HM§†‡48 hrs
2000
1500

c
1000
500
0

CPM (Counts per minute)

1000

X Data

HM§† 72 hrs
800
600

0uM Mino
1uM Mino
2uM Mino
4uM Mino

c
0uM Mino
a
1uM Mino
2uM Mino
4uM Mino

400
200

c

0

0 Gy

2 Gy

4 Gy

6 Gy

8 Gy
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Cell Viability Assay
Figure 4.8 shows that there was a main effect of radiation on A172 cells at each
time point due to an overall decrease in the percentage of viable cells with increasing
dose (P<0.05). There were no drug effects or interactions on this cell type.
A main effect of radiation also existed for T98G cells (Figure 4.9) at each time
point (P<0.05; Figure4. 9) due to reduction in percent viability mostly at the higher two
doses of 6 Gy and 8 Gy that was only apparent when the effects of the drug were taken
into account. There were no differences among individual groups in post-hoc analysis
compared to 0 Gy. There was also a main effect of drug at 48 h (P<0.05). When the
effects of radiation were taken into account, the 2 μM drug concentration generally
resulted in greater % viability compared to the 0 μM. However, this response was not
significant in post-hoc analysis.
For U87MG cells (Figure. 4.10), there were main effects of radiation noted at
every time point (P<0.05). At 24 h, this was due to slight increases in viable cells
compared to 0 Gy controls. However, at 48 and 72 h radiation tended to decrease
viability, although statistical significance was not obtained in post-hoc analysis. There
was also a main effect of drug at 48 h, presumably due to overall differences between the
2 μM and 4 μM concentrations (P<0.05 when the effects of radiation were taken into
account), but post-hoc analysis showed no significant differences between the various
levels of the drug compared to 0 μM.
For the non-tumor cell line HA (Figure. 4.11), both radiation and the drug had
significant main effects at each time point (P<0.05). While radiation generally decreased
the percentage of viable cells, particularly at the later time points, there were consistent
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(though not always statistically significant in post-hoc analysis) drug-induced increases
with 1 μM compared to 0 μM and 4 μM.
There was significant impact of radiation on the HM cells at each time point
(P<0.05), as shown in Figure 4.12. Radiation generally decreased the percentage of
viable cells, again particularly at the later time points. The drug at 4 μM concentration at
24 hrs, generally resulted in a significantly lower percent viability from the 0 μM control
(P<0.05, when the effects of radiation were taken into account), thus resulting in main
effect of drug (P<0.05). However, this difference between 0 and 4 μM was only
significant at 6 Gy (P<0.05).
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Figure. 4.8. Cell Viability Assay for Glioblastoma Cell Line A172. Each bar represents
the mean ± SEM for n=8-10 samples/group. Two-way ANOVA: §, P<0.05 for main
effect of radiation.
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Discussion
Some researchers believe that apoptosis is the most significant response of the
adult brain to damage caused by ionizing radiation (Bálentová, Hajtmanová et al. 2011).
Although the CNS is relatively radioresistant and significant damage occurs at higher
doses, several studies have reported that exposure to relatively low doses of radiation can
significantly alter the proliferation of neural stem cells in the adult neurogenic regions of
the brain and induce apoptosis of the neural precursor stem cell pool (Monje, Mizumatsu
et al. 2002; Mizumatsu, Monje et al. 2003; Monje, Toda et al. 2003; Raber, Rola et al.
2004; Andres-Mach, Rola et al. 2008; Bálentová, Hajtmanová et al. 2011). Adult
neurogenesis occurs in the subventricular zone (SVZ) of the lateral ventricle and the
subgranular zone (SGZ) of the hippocampal dentate gyrus (Temple and Alvarez-Buylla
1999; Gage 2000). Minocycline suppresses the microglial production of IL-1β, TNF-α
and IL-6 (Kielian, Esen et al. 2007). These anti-inflammatory effects of minocycline on
the brain are thought to be responsible for its neuroprotective properties. In our study,
minocycline alone increased the levels of IL-10 significantly from the non-drug treated
irradiated counterpart and modified the radiation response for the cytokine on day 4.
Increase in IL-10 upon treatment with minocycline is consistent with the literature (Lee,
Yune et al. 2003; Shi, Diez-Freire et al. 2010). IL-10 is an anti-inflammatory cytokine
which also possesses neuroprotective qualities (Brewer, Bethea et al. 1999; Bachis,
Colangelo et al. 2001; Burkovetskaya, Levin et al. 2007). Neuroprotective properties of
IL-10 have been attributed to its ability to suppress pro-apoptotic proteins (Bachis,
Colangelo et al. 2001). IL-10 is currently being evaluated in clinical trials for suppressing
inflammation (Asadullah, Sterry et al. 2003).
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The drug significantly increased VEGF levels in the 1 and 2 Gy irradiated groups
on day 4, but had no effect on day 32. Increase in VEGF levels in response to
minocycline has also been reported by others (Hollborn, Wiedemann et al. 2010; Sakata,
Niizuma et al. 2012). VEGF has been reported to be neuroprotective (Jin, Mao et al.
2000). It promotes neurogenesis in ischaemic brain (Sun, Jin et al. 2003) and prevents
neuronal loss in traumatic brain injury (TBI) (Ma, Liu et al. 2011). A protective role of
VEGF against radiation injury has been reported by Warner- Schmidt et al., who showed
that low doses of radiation can lead to lowered hippocampal neurogenesis and this can be
reversed by mechanisms involving VEGF increase (Warner-Schmidt, Madsen et al.
2008). Although VEGF is indicated in late radiation-induced blood brain barrier (BBB)
disruption, no changes in early levels of VEGF have been reported following radiation
(Tsao, Li et al. 1999; Li, Ballinger et al. 2001). Although we did not determine the source
of this cytokine, astrocytes are a likely source for VEGF in response to stress. In the in
vitro studies presented here, we found that radiation drastically reduced viability, even at
2 Gy, suggesting that a similar decrease could occur in vivo. However, the drug-treated
HA cells (astrocytes), showed increased viability at 2 Gy at 1 μM concentration
(P<0.05). This might explain the increase in VEGF levels.
Although the drug increased levels of IL-13 and IL-15 at 1 Gy, and generally
decreased radiation-induced increases in IP-10, it did not modify the radiation response
for any of these cytokines, which would otherwise have supported our hypothesis. There
is an indication for the neuroprotective role of IL-13 (Rossi, Mancino et al. 2011) which
is also an anti-inflammatory cytokine. Although IL-15 has been reported to be a proinflammatory cytokine, several studies have suggested an anti-inflammatory role for this
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cytokine and its receptor, i.e., IL-15Rα (Pan, Wu et al. 2011). Beneficial effects of IL-15
have been indicated by several researchers. It increases proliferation of adult neural
precursor cells and IL-15 deficient mice have lowered neurogenesis (Gomez-Nicola,
Valle-Argos et al. 2011). IP-10, also known as C-X-C motif chemokine 10 (CXCL10), is
a protein implicated in several neuronal pathologies (Vlkolinsky, Siggins et al. 2004).
Minocycline alone reduced the expression of IL-1β in the brain on day 32.
Reduction in IL-1β levels in the brain with minocycline treatment has also been observed
by other researchers (Tikka, Fiebich et al. 2001; Choi, Kim et al. 2007). IL-1β has been
implicated in numerous neurodegenerative diseases of the CNS and is reported to be
neurotoxic (Rothwell 1998; Lucas, Rothwell et al. 2006; Pott Godoy, Tarelli et al. 2008).
As mentioned earlier, minocyline increased the viability of human astrocytes at
the lowest dose of 1μM used in our study. Some reports have indicated that minocycline
did not exert any toxicity on astrocytes between 1-75μM concentrations and actually
increased viability and proliferation between 20-40 μM (Kernt, Neubauer et al. 2010),
whereas others have reported no such beneficial effects (Matsukawa, Yasuhara et al.
2009). The reason for this discrepancy could be due to the fact that the drug was tested in
two different experimental models , i.e., optic nerve head astrocytes in vitro and a mouse
model of ischemic stroke, respectively.. The drug may simply be inhibiting the division
of the cells while simultaneously increasing astrocyte viability at the low dose of 1 μM.
Several studies have indicated new functions of astrocytes, different from their
role in neuronal inflammation (Barreto, White et al. 2011). They can play roles in
increasing neuronal survival. Astrocytes have been shown to facilitate adult neurogenesis
(Song, Stevens et al. 2002), secretion of neurotrophic factors, elimination of excess
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glutamate to promote neuronal survival (Swanson, Ying et al. 2004) and rebuilding the
BBB (Kaur and Ling 2008; del Zoppo 2009). Astrocytes also release glutathione and
superoxide dismutase (SOD) to promote neuronal survival from free radicals following
stroke (Dringen 2000; Dringen, Gutterer et al. 2000; Bambrick, Kristian et al. 2004).
They could be performing similar functions following radiation-induced generation of
free radicals.
Minocycline reduced the proliferation of microglial cells without affecting their
viability at the lower drug doses used in our study. However, viability was only reduced
at 6 Gy in the 4 μM drug-treated cells at 24 h. Over-expression of IL-1α and β from
microglia, contributes to neurodegeneration (Griffin 2006). A significant decrease in
neurons was associated with a simultaneous increase in activated microglia (Fike, Rosi et
al. 2009). Rapidly proliferating microglia can contribute to increased inflammation
resulting in neuronal apoptosis. Markovic et al. indicated the potential of minocycline in
suppressing glioma spread (Markovic, Vinnakota et al. 2011).
With respect to the tumor cell lines, minocycline did not increase their level of
DNA synthesis. In fact, it reduced the incorporation of 3H-TdR by U87MG cells at all
three time points. Furthermore, T98G cells had lower DNA synthesis at 24 h at the
highest concentration of the drug. When looking at the viability profile of the cancer cell
lines, it was clear that the drug did not increase the percentage of viable A172, T98G and
U87MG cells.
In our microarray analysis of brain samples for cytokine- and neurotoxicty-related
gene profiles on day 32, radiation exposure up-regulated gene expression of the IL family
(Il11, Il12b, Il15, Il17c, Il20 and Il24), IL-1 family (Il1f6, Il1f8 & Il1f10), TNF
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superfamily (Tnfrsf11b & Tnfsf12), growth differentiating factors (Gdf1, 2, 10 & 15) and
bone morphogenetic proteins (Bmp, 5, 6, 7 & 10). With the combined treatment
(minocycline + radiation), the expression of many of these genes no longer met the
criterion for being significantly different from 0 Gy controls (i.e. P<0.05 and fold change
> 1.5). Generally this means that the expression level was essentially equivalent to
normal. However, in some cases fold changes in the combined treatment groups did not
necessarily change substantially compared to radiation only, but significance was no
longer found due to increased variability. For example, Bmp6 was significantly upregulated by more than 8-fold in both irradiated groups (with and without the drug).
However, expression in the drug-treated group was elevated (fold change = 6.9), but
statistical significance was not achieved (P>0.1). However, in the drug-treated group, the
fold change was elevated (fold change = 6.9) but significance was not achieved (P>0.1).
This inconsistency may be addressed by increasing the sample size.
Radiation increased the expression of Gdf, but when the drug was added the
expression was lowered or no longer significantly different from control. Although some
Gdfs are reported to be neuroprotective (Sullivan, Opacka-Juffry et al. 1999), the reason
why they were not increased in the presence of minocycline could be due to decreased
damage to neurons, hence the lessened need to promote recovery. This can be verified
through histological examination of brain tissue. Another factor to consider is the time
point of analysis, which was day 32 and neurogenic factors might not have been essential
at that time point. The drug increased the expression of Bmp5 and its expression went up
even further in the combined treatment group. Bmp5 has been indicated in ameliorating
Parkinson’s disease, a condition that includes brain inflammation(Brederlau, Faigle et al.
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2002). Some reports however, indicate that Bmp signaling leads to reduced
neurogenesis(Groppe, Greenwald et al. 2002; Gobeske, Das et al. 2009) and inhibiton of
Bmp signaling which lead to increased neurogeneis in adult SVZ(Lim, Tramontin et al.
2000). In contrasting evidence, Colak et al indicated that Bmp4 signaling was crucial for
neurogenesis in stem cells(Colak, Mori et al. 2008). Increase in Bmp7 was observed only
in the combined treatment group. However the drug alone had no impact on Bmp 10.
IL-1 family members contribute to brain inflammation (Wang, Meinhardt et al.
2005; Goldbach-Mansky and Kastner 2009) and several of these members were no longer
up-regulated in minocycline-treated groups. Il12b (up-regulated by radiation alone, but
not in either of the minocycline groups) encodes a segment of the pro-inflammatory IL12 cytokine, which is secreted mostly by microglia and not astrocytes (Becher, Dodelet et
al. 1996; Aloisi, Penna et al. 1997). IL-17, another potent inflammatory cytokine
important in brain inflammation, was no longer up-regulated with the addition of the drug
(Huppert, Closhen et al. 2010). Although we observed an increase in IL-15 protein with
the drug on day 4, this was not evident on day 32. This is consistent with our day 32
microarray results for this cytokine.
Some of the inflammatory cytokines that are members of the Tnf family were upregulated by radiation. Many neurodegerative diseases are related with the increased
expression of TNF(Tansey and Szymkowski 2009). Tnfsf11 encodes TNF-11, also
known as receptor activator of nuclear factor kappa-B ligand or (RANKL) which is
implicated in osteoclastogenesis. Anti-RANKL treatments are being developed for
inflammatory diseases(Anandarajah and Schwarz 2006; Ferrari-Lacraz and Ferrari 2011).
The reduction in TNF-α in the brain with the use of minocycline has previously been
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reported (Park, Shin et al. 2011). This suggests that minocycline may be useful as a
neuroprotective agent and may reduce the risk for neurocognitive deficits. It is to be
noted, however, that the expression of Tnfsf10 and Tnfsf11 went up in the combined
treatment group. Cd70, which is secreted by glioblastomas and promotes inflammation
(Held-Feindt and Mentlein 2002; Manocha, Rietdijk et al. 2009) was among the genes
that was no longer significantly different in the combined treatment group compared
dH2O + 0 Gy. The interaction of the drug with radiation and how it modifies the radiation
response is essential to further understand the implications of utilizing this drug in a
clinical setting.
While radiation up-regulated the gene expression for Bcl-2 interacting killer
(Bik), nitric oxide synthase trafficker (Nostrin) and heat shock 70kDa protein 5 (Hspa5),
addition of minocycline resulted in the differences to be no longer significantly different
from 0 Gy. Bik encodes a pro-apoptotic protein while the protein derived from Nostrin
induces the synthesis of nitric oxide. Reduction in the expression of Nostrin is consistent
with reports showing that minocycline inhibits nitric oxide (Sadowski and Steinmeyer
2001; Lee, Yune et al. 2004).
Overall, our data increase knowledge on the potential of minocycline as a
neuroprotective agent in a radiation setting. Major promising findings of this study are
that the drug did not protect at least two of the human tumor cell lines (A172 and
U87MG) and increased production of cytokines that are neuroprotective and neurogenic
in an intact mammalian model. Further studies with this drug are needed to confirm its
full potential as a radioprotective agent of the CNS and whether it can reduce radiationinduced cognitive decline.
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CHAPTER FIVE
DISCUSSION

There are many salient features of our research. This is the first study that tested
the radioprotective potential of minocycline after whole-body irradiation. The study was
undertaken primarily to evaluate the prospective utilization of minocycline as a
radioprotective agent for ARS, with main emphasis towards hematopoietic recovery and
alleviation of radiation-induced damage to the CNS. The overall findings are very
promising and support further testing of minocycline for clinical use.
It is well established that ionizing radiation impairs hematopoiesis through
numerous mechanisms. This includes direct destruction of the hematopoietic stem cells,
as well as alteration in the capacity of bone marrow stromal elements to support or
maintain hematopoiesis {Dainiak, 2002 #678}. Evidence in the literature suggests that
tetracyclines can be robust radioprotectors of the hematopoietic system with potential
utility in radiation emergencies and anticancer radiotherapy. For instance, tetracyclines
have been reported to have radioprotective properties for hematopoietic cells by Kim et
al. (Kim, Pollard et al. 2009).
In Chapters 2 and 3, we presented evidence that minocycline up-regulated several
cytokines that are potentially useful for speeding up hematopoietic recovery. This was
manifested as a reduction in radiation-induced changes in the splenic and circulating
leukocyte profiles. As expected, radiation caused depression of the blood and spleen
WBC populations. The drug counteracted the radiation-induced declines in
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monocytes/macrophages, granulocytes, NK cells, T cells and CD8+ T cells in the spleen
on day 4 post-IR. This correlates with the increased splenic production capacity for
cytokines such as G-CSF, GM-CSF, IL-1α and IL-1β at this early time point. Even on
day 32, a depressive effect of radiation on B cell population in the spleen was still
evident. Since the major function of the B lymphocytes is to produce antibodies against
foreign materials (including bacteria and other microbes), the radiation-induced
depression in these cells could increase risk for infection. However, the drug-treated
groups showed a reversal the B cell population at 2 and 3 Gy, i.e., rendering the level
essentially equivalent to normal.
Our hypotheses included the premise that minocycline would increase antiinflammatory cytokines in the spleen and brain. Although we expected the drug to
selectively up-regulate only anti-inflammatory cytokines, the results of our study showed
that both pro- and anti-inflammatory cytokines were increased. There are some reports
suggesting that minocycline can stimulate the production of pro-inflammatory cytokines
such as TNF-α and IFN-γ in addition to the anti-inflammatory cytokine IL-10
(Kloppenburg, Brinkman et al. 1996; Houri-Haddad, Halabi et al. 2008). However, the
up-regulation may be a result of monocyte stimulation with lipopolysaccharide prior to
treatment with minocycline as postulated in the report by Kloppenburg et al. Also, it
cannot be ruled out that minocycline may trigger different pathways leading to antiinflammatory or pro-inflammatory cytokine/chemokine production depending on the
source of cell stimulation and the effects of tissue microenvironment. This may at least
partly explain why a mixed response in cytokine analysis was observed in the present
study. In addition, with respect to the spleen, it should also be pointed out that cytokine
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levels were quantified in supernatants after activation of the TCR/CD3 complex.
Therefore, the generated cytokines were representive of the organ’s ability to respond to a
stimulus that was initially focused on activation of essentially all mature T lymphocytes.
The use of an antibiotic has several advantages because a serious consequence of
hematological syndrome is a period of 30-60 days during which the subject is highly
susceptible to infections. Infection accounts for a substantial proportion of patient
mortality rate. In one study, administration of antibiotics to irradiated dogs lowered the
mortality rate(Jackson, Sorensen et al. 1959). Minocycline, is particularly useful as an
antibiotic since it is a broad-spectrum tetracycline derivative with widespread
accessibility and low cost and is available as an oral formulation. The oral route would be
ideal when treatment is needed for a large population exposed to radiation. Furthermore,
the drug is FDA approved and is commonly used in the treatment of infections related to
S. aureus and N. meningitides and acne. The safety profile, clinical features and side
effects of minocycline are well characterized. It is relatively well tolerated by patients.
However, an effective dose of minocycline needs to be determined if it is ever to be used
as a radioprotectant for radiation victims or in occupational settings such as space travel.
Several aspects need to be taken into account for utilizing a compound as a
radioprotectant. In order to be an effective radioprotectant, the compound in question
should not protect the tumor. The agent may block a cell in a non-proliferative state, i.e.,
force it to remain quiescent, thus reducing the efficacy of radiation on the destruction of
rapidly proliferating cells (Greenberger 2009). Another major and often overlooked
concern is that the agent may provide initial protection against irradiation of normal cells,
but allow delayed effects to be expressed in their progeny (Dziegielewski, Goetz et al.
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2010). These delayed effects could include cell transformation and subsequent
progression to malignancy.
With respect to the brain, minocycline was tested for its ability to protect normal
cells that reside in the CNS (astrocytes and microglia) versus glioblastoma cells. A
promising finding of our study is that the drug did not protect tumor cells. Although we
saw a drug effect for T98G cells at 48 hours (i.e. viability was consistently higher at 2
μM compared to 0 μM when the effects of radiation were taken into account), this was
not found at any other time points and doses of drug or radiation, suggesting that the drug
does not protect glioblastoma cells. Furthermore, the drug increased the viability of
astrocytes when used at 1 μM. There was no effect on viability of the microglia. The
difference in responses observed between microglia and astrocytes might be attributed to
the fact that they are different cell types. Microglia (cells of macrophage lineage that
reside in the brain) are more efficient than astrocytes at antigen processing and
stimulation of Th1 lymphocyte lymphocytes that promote cell-mediated immune
responses that can lead to excessive and prolonged inflammation if not properly
controlled. There is also some evidence that astrocytes restimulate responses of the Th2
subset during chronic inflammation (Aloisi, Ria et al. 1998) and possess a homeostatic
role, assisting in recovery from Th1 cell-mediated inflammation in the CNS. It has been
reported that minocycline and astrocytes may both be factors in the reduction of T cell
activation and proliferation. Research on motor neurons in a model of amyotrophic lateral
sclerosis (ALS) revealed that the neurons were being protected by glutathione secretion
from astrocytes in a model of ALS (Vargas, Johnson et al. 2008). Another study
demonstrated the protection of neurons from apoptosis by minocycline during ionizing
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radiation (Tikka, Usenius et al. 2001). The differential effect of the drug on tumor versus
non-tumor cells gives further support for testing minocycline as a neuronal
radioprotectant.
The impact of minocycline on the brain could have implications beyond
inflammation. Cytokines can influence cognition through various mechanisms resulting
in both neurogenesis and neurodegeneration (Wilson, Finch et al. 2002). Research
indicates that inflammatory mechanisms in the brain may promote cognitive decline and
neurodegeration through cytokine-mediated interactions (Wilson, Finch et al. 2002).
Minocycline influenced the levels of several key cytokines in the brain that support our
hypothesis. Information on the roles of IL-1β, IL-10 and VEGF in CNS inflammation
and neuroprotection is widely recognized. Several researchers have reported that
increased IL-1β during brain inflammation can lead to various pathologies (Belikova,
Glumac et al. 2009; Plane, Shen et al. 2010). The literature supports the reduction in IL1β levels in the brain by minocycline (Belikova, Glumac et al. 2009).
The increased expression of VEGF in the brain that was observed after treatment
with minocycline is consistent with findings from other researchers (Sakata, Niizuma et
al. 2012). Some researchers have also reported VEGF increase in retinal pigment
epithelial cells (RPE) by minocycline (Hollborn, Wiedemann et al. 2010). While the drug
increased the VEGF levels in the brain, it decreased VEGF levels in the spleen
supernatants after anti-CD3 stimulation of T cells, but only on day 4. The reason(s) for
the difference in VEGF production by the splenocytes and CNS is(are) not known.
However, there are reports that minocycline decreases VEGF levels in experimental
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models with tumors, suggesting that the drug has anti-angiogenic potential (Kakeji and
Teicher 1997). Several speculations can be made in this regard.
IL-10 is a potent anti-inflammatory cytokine thought to help prevent cognitive
decline (Richwine, Sparkman et al. 2009). This cytokine was increased in both spleen
supernatants and brain from at least some of the irradiated groups that were treated with
minocycline. These findings support the premise that the drug has potential to counteract
radiation damage in both organs.
Overall, the anti-inflammatory effects of minocycline were more evident in the
brain compared to the spleen with respect to the cytokine analysis. Although upregulation of important pro-inflammatory cytokines in the spleen was also noted, this
may be essential to recovery of the radiation-induced damage to the hematopoietic
system. Pro-inflammatory cytokines can protect hematopoietic stem cells against
radiation damage (Neta 1997). It remains to be determined whether minocycline will be
able to restore hematopoietic populations and protect the CNS in populations (including
radiotherapy patients) exposed to radiation doses higher than the maximum 3 Gy used in
the present study. Higher doses of radiation are generally administered to the CNS during
radiotherapy, owing to the relative radioresistance of the brain. This, however, is the first
study of its kind highlighting the potential of minocycline as a radioprotective agent for
this purpose.

Conclusions and Future Directions
Several broad conclusions can be drawn from this study:
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(i) Minocycline treatment up-regulated several hematopoietic recovery-related
cytokines on days 4 and 32 post-irradiation. This was evident in the splenocyte
population profiles mainly on day 4 with increases in macrophages, granulocytes, NK
and CD8+ T cells. On day 32, drug-induced enhancement was noted in B cells.
(ii) Minocycline alone up-regulated IL-1α, which is a known radioprotective
cytokine in spleen supernatants, as well as GM-CSF and G-CSF that accelerate
neutrophil recovery at both time points.
(iii) Drug treatment reduced the levels of TNF-α, IFN-γ and MIP-1α on day 4 and
IFN-γ on day 32 in spleen supernatants i.e., cytokines that inhibit hematopoiesis.
(iv) The drug reversed the radiation-induced decrease in IL-10 in the brain on day
4, while increasing the level of VEGF. It also lowered IL-1β on day 32.
(v) Finally, in vitro work indicates that the drug protected astrocytes from
radiation damage, as evidenced by the increase in post-radiation viability at lower drug
doses. However, it did not protect tumor cells from radiation. There were no
corresponding increases in post-irradiation viability of tumor cells. In addition, the drug
reduced DNA synthesis by U87MG cells at all time points and on T98G cells at 24 hours
after irradiation, but there was no drug effect on the A172 cells. Relatively low DNA
synthesis was also noted for the normal astrocytes and microglia in presence of the drug.
Future studies should include a range of minocycline concentrations and routes in
an in vivo model system to determine optimal treatment conditions for radioprotection.
Analysis at time points between day 4 and day 32 are needed to confirm the speed at
which the drug helps with recovery of hematopoietic cell populations. Identification of
specific cellular and molecular mechanisms by which minocycline facilitates
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hematopoietic recovery should also proceed. Studies involving the effect of the drug on
hematopoietic stem cells in the bone marrow would reveal whether the drug actually
protects them (and/or the more mature progenitor populations) from radiation-induced
death. Other studies involving measurement of ROS levels in the cells can determine if
scavenging free radicals is an important mechanism through which the drug acts. Effect
of minocycline on neural stem cells would help determine its potential in promoting
neurogenesis. Analysis of pathways affected through minocycline involving differential
effects on tumor versus non-tumor cells is critical for further testing of this drug as a
normal tissue protectant in the context of radiotherapy.
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APPENDIX
(A) FOLD CHANGES IN CYTOKINE GENE EXPRESSION IN
LIVER TISSUE VS DH2O + 0 GY ON DAY 32 POST-IR (P VALUE
<0.05 AND FOLD CHANGE >1.5)

Symbol
Il17f
Gdf10
Tnfsf10
Il20
Cd70
Il1f8
Il19
Gdf15
Tnfsf9
Il7
Il1b
Tnfsf14
Il27
Tnfsf4

dH2O
+3 Gy
-2.48
-1.70

Mino
+ 0 Gy

-1.62
1.55
1.57
1.57
1.80

-1.55

Mino
+3 Gy
-2.70

-2.47
1.52
1.65

-3.16
-2.23
-1.78
-1.61
3.24
-1.99
1.72

Gene Description
Interleukin 17F
Growth Differentiation factor 10
Tumor necrosis factor (liagnd) superfamily, member
11
Interleukin 20
CD70 antigen
Interleukin 1 family, member 8
Interleukin 1 family, member 9
Growth differentiation factor 15
Tumor necrosis factor(ligand) superfamily, member 9
Interleukin 7
Interleukin 1 beta
Tumor necrosis factor(ligand) superfamily member 14
Interleukin 27
Tumor necrosis factor(ligand) superfamily mamber 4

The data were obtained from n = 4 mice/group. Radiation reduced the expression
of Il17, Gdf10, Tnfsf10 while increasing Il20, Cd70, Ilf8 and Ilf9. When minocycline was
added to these groups, this difference was no longer significant from 0 Gy dH2O. In
contrast, adding minocycline increased the radiation response for Tnfsf10 (i.e. further
reduced the expression). The drug decreased the expression of Gdf15, Tnfsf9, Il7, Il1b,
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while increasing Tnfsf14 and the radiation did not have an impact on any of them. The
combined treatment decreased Il27 and increased Tnfsf4 while radiation alone or drug
alone did not have any effect on the expression of either gene.

160

